

Steven R Feldman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2437716/publications.pdf>

Version: 2024-02-01

1,092
papers

37,702
citations

5268

83
h-index

5829

161
g-index

1116
all docs

1116
docs citations

1116
times ranked

20703
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing adults' beliefs about the motivations for indoor tanning. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2023, 39, 66-68.	1.5	0
2	Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis. <i>Annals of Pharmacotherapy</i> , 2023, 57, 86-98.	1.9	16
3	Review of Tralokinumab in the Treatment of Atopic Dermatitis. <i>Annals of Pharmacotherapy</i> , 2023, 57, 333-340.	1.9	3
4	Review of Ruxolitinib in the Treatment of Atopic Dermatitis. <i>Annals of Pharmacotherapy</i> , 2023, 57, 207-216.	1.9	5
5	Patients who feel more accountable are more adherent: A clinical study in patients with xerosis. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 481-483.	1.2	1
6	Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1208-1212.	2.2	7
7	Treatment of keratosis pilaris and its variants: a systematic review. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1231-1242.	2.2	10
8	College aspirations, gender sexuality alliances, and teacher support among diverse LGBTQ youth. <i>Educational Review</i> , 2022, 74, 281-297.	3.7	4
9	Topical methotrexate in dermatology: a review of the literature. <i>Journal of Dermatological Treatment</i> , 2022, 33, 512-517.	2.2	17
10	Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1511-1520.	2.2	4
11	Dapsone as corticosteroid-sparing therapy for Sweet syndrome. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 677-679.	1.2	7
12	Oral dapsone for the treatment of generalized granuloma annulare: A retrospective case series. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 911-914.	1.2	6
13	Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1670-1675.	2.2	7
14	Frequency of procedural and medical treatments of actinic keratosis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 916-918.	1.2	3
15	Patient assessment of 5-fluorouracil and imiquimod for the treatment of actinic keratoses: a retrospective study of real-world effectiveness. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2075-2078.	2.2	5
16	Controversial cardiovascular and hematologic comorbidities in atopic dermatitis. <i>Archives of Dermatological Research</i> , 2022, 314, 317-324.	1.9	7
17	Hydroxychloroquine for generalized granuloma annulare: 35% response rate in a retrospective case series of 26 patients. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 144-147.	1.2	4
18	Abametapir for the Treatment of Head Lice: A Drug Review. <i>Annals of Pharmacotherapy</i> , 2022, 56, 352-357.	1.9	10

#	ARTICLE	IF	CITATIONS
19	1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses. <i>Annals of Pharmacotherapy</i> , 2022, 56, 494-500.	1.9	10
20	Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2270-2277.	2.2	11
21	Patient and caregiver preferences on treatment attributes for atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2225-2233.	2.2	9
22	Methotrexate for generalized granuloma annulare: A 60% response rate in a retrospective case series of 15 patients. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 201-203.	1.2	6
23	Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2503-2509.	2.2	10
24	Assessing the relationship between topical corticosteroid phobia and susceptibility to misinformation in patients with atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	2
25	Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 221-231.	3.0	11
26	Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population. <i>Dermatology</i> , 2022, 238, 438-447.	2.1	7
27	The evolving atopic dermatitis management landscape. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 517-526.	1.8	15
28	The impact of demographic and socioeconomic status on patient perception of barriers to outpatient dermatologic care. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 864-865.	1.2	2
29	Developing electronic monitor adapters for dermatologic medication containers: A methods paper. <i>Skin Research and Technology</i> , 2022, 28, 371-373.	1.6	0
30	Hidradenitis suppurativa may impact clothing patterns even in patients with mild disease and symptoms: an observational study. <i>British Journal of Dermatology</i> , 2022, 187, 250-251.	1.5	3
31	Review of the holistic management of pediatric atopic dermatitis. <i>European Journal of Pediatrics</i> , 2022, 181, 1363-1370.	2.7	2
32	Choosing the appropriate pharmacotherapy for Morgellons disease: an expert perspective. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 527-530.	1.8	1
33	The presence of accountability in digital interventions targeting non-adherence: A review. <i>Patient Education and Counseling</i> , 2022, , .	2.2	1
34	How suitable are JAK inhibitors in treating the inflammatory component in patients with alopecia areata and vitiligo?. <i>Expert Review of Clinical Immunology</i> , 2022, , 1-3.	3.0	4
35	Tazarotene 0.045% Lotion: A Novel Retinoid Formulation. <i>Annals of Pharmacotherapy</i> , 2022, , 106002802110721.	1.9	1
36	Atopic Dermatitis and Psoriasis are Diagnosed Clinically and Treated Empirically. <i>Dermatology and Therapy</i> , 2022, 12, 611-614.	3.0	1

#	ARTICLE	IF	CITATIONS
37	Comparing available JAK inhibitors for treating patients with psoriasis. Expert Review of Clinical Immunology, 2022, 18, 281-294.	3.0	9
38	Tacrolimus and spirocyclic for complex aphthosis: outcomes in 21 patients. Journal of the American Academy of Dermatology, 2022, , .	1.2	0
39	Views and Beliefs of Vitiligo Patients in Online Discussion Forums: A Qualitative Study. , 2022, 109, 49-53.		0
40	Why Do Patients in the United States Seek Care from Dermatologists?. Dermatology and Therapy, 2022, 12, 1065-1072.	3.0	5
41	Percutaneous egression: What do we know?. Skin Pharmacology and Physiology, 2022, , .	2.5	0
42	Strategies to Optimize Adherence in Patients with Mycosis Fungoides. Cells, 2022, 11, 113.	4.1	1
43	An overview of benvitimod for the treatment of psoriasis: a narrative review. Expert Opinion on Pharmacotherapy, 2022, 23, 327-333.	1.8	2
44	Accountability in reminder-based adherence interventions: A review. Patient Education and Counseling, 2022, 105, 2645-2652.	2.2	3
45	Typical Scurvy in an Atypical Patient: Case Report. SN Comprehensive Clinical Medicine, 2022, 4, .	0.6	0
46	Greater rosacea severity correlates with greater adherence and improvement in a clinical study. Journal of the American Academy of Dermatology, 2022, , .	1.2	2
47	Patient willingness to receive full-body skin exams based on the sex and/or gender and training level of provider: a survey study. Clinical and Experimental Dermatology, 2022, , .	1.3	0
48	Internet-based survey intervention improves adherence to methotrexate among psoriasis patients. Journal of Dermatological Treatment, 2022, 33, 2784-2789.	2.2	3
49	The Role of Anticipation in Patient Adherence. Southern Medical Journal, 2022, 115, 315-316.	0.7	0
50	Impact of Unit-Dosing of Sunscreen on Adherence at Golf Tournaments. Journal of Cutaneous Medicine and Surgery, 2022, 26, 528-529.	1.2	1
51	Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?. Expert Opinion on Biological Therapy, 2022, 22, 1439-1441.	3.1	1
52	Evaluation of Methotrexate in the Management of Sweet Syndrome. Journal of Cutaneous Medicine and Surgery, 2022, 26, 532-533.	1.2	4
53	Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured population. Journal of Dermatological Treatment, 2021, 32, 595-602.	2.2	12
54	Secukinumab rapidly improves EQ-5D health status in patients with psoriasis: Pooled analysis from four phase 3 trials. Journal of Dermatological Treatment, 2021, 32, 709-715.	2.2	4

#	ARTICLE	IF	CITATIONS
55	Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. <i>Journal of Dermatological Treatment</i> , 2021, 32, 693-700.	2.2	7
56	Is topical treatment effective for psoriasis in patients who failed topical treatment?. <i>Journal of Dermatological Treatment</i> , 2021, 32, 41-44.	2.2	4
57	PrabotulinumtoxinA-xvfs for the Treatment of Moderate-to-Severe Glabellar Lines. <i>Annals of Pharmacotherapy</i> , 2021, 55, 354-361.	1.9	1
58	Adherence to Drug Therapy. , 2021, , 34-39.e1.		0
59	Long-term efficacy of certolizumab pegol for psoriasis. <i>British Journal of Dermatology</i> , 2021, 184, 588-589.	1.5	0
60	The importance of publications, research, volunteer, and work experience in dermatology residency applicants. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e99-e100.	1.2	3
61	Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry—based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	2.9	136
62	Evidence is lacking for or against palmoplantar pustulosis treatments: what does this mean for the clinician. <i>British Journal of Dermatology</i> , 2021, 184, 990-990.	1.5	0
63	Evaluating calcipotriene 0.005% foam for the treatment of plaque psoriasis of the scalp and body in patients aged 12 years and older. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 543-547.	1.8	0
64	Immunogenicity of Biologic and Biosimilar Therapies for Psoriasis and Impact of Novel Immunoassays for Immunogenicity Detection. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 221-231.	6.7	2
65	An update on the impact of depression on the treatment of psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 695-703.	1.8	9
66	A review of secukinumab in psoriasis treatment. <i>Immunotherapy</i> , 2021, 13, 201-216.	2.0	10
67	Comparing prescribing patterns for topical corticosteroids based on their FDA indication by age. <i>Pediatric Dermatology</i> , 2021, 38, 115-118.	0.9	2
68	Treatment practices for psoriasis and how they are changing. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 579-581.	1.2	5
69	Reply to Letter to the Editor. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e111-e112.	1.2	0
70	Treating a chronic disease without chronic adherence. <i>Journal of Dermatological Treatment</i> , 2021, 32, 131-131.	2.2	0
71	Do increased risks of cancer mean we need to change our approach to treatment?. <i>Journal of Dermatological Treatment</i> , 2021, 32, 1-2.	2.2	3
72	Mycophenolate mofetil for the treatment of cutaneous lichen planus: A retrospective case series. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1091-1094.	1.2	2

#	ARTICLE	IF	CITATIONS
73	Abnormal liver function tests in acne patients receiving isotretinoin. <i>Journal of Dermatological Treatment</i> , 2021, 32, 469-472.	2.2	8
74	Psoriasis patient preferences for topical drugs: a systematic review. <i>Journal of Dermatological Treatment</i> , 2021, 32, 478-483.	2.2	26
75	Difference in vasoconstrictors: oxymetazoline vs. brimonidine. <i>Journal of Dermatological Treatment</i> , 2021, 32, 137-143.	2.2	14
76	Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status. <i>Journal of Dermatological Treatment</i> , 2021, 32, 203-211.	2.2	9
77	Bromhidrosis Treatment Modalities: A Literature Review. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	6
78	Improving management of psoriasis patients receiving biological treatment: A qualitative approach. <i>Nursing Open</i> , 2021, 8, 1283-1291.	2.4	8
79	Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2021, Volume 14, 55-63.	1.8	2
80	Caregiver Preferences for the Treatment of Childhood Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 336-338.	1.2	1
81	Tolerability of and Adherence to Topical Treatments in Atopic Dermatitis: A Narrative Review. <i>Dermatology and Therapy</i> , 2021, 11, 415-431.	3.0	18
82	Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the Acne Treatment Paradigm. <i>Annals of Pharmacotherapy</i> , 2021, 55, 1297-1299.	1.9	0
83	Patient-reported outcomes of topical therapies in actinic keratosis: A systematic review. <i>Dermatologic Therapy</i> , 2021, 34, e14833.	1.7	17
84	The next quantum leap forward? Bimekizumab for psoriasis. <i>Lancet, The</i> , 2021, 397, 446-448.	13.7	2
85	Speed of Psoriasis Treatment Response for Biologic Agents: A Review of Phase III Clinical Trials. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 99-105.	0.7	1
86	Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: a drug evaluation. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1107-1118.	1.8	1
87	Mycophenolate mofetil as adjunctive therapy to corticosteroids for the treatment of pyoderma gangrenosum: a case series and literature review. <i>International Journal of Dermatology</i> , 2021, 60, e486-e492.	1.0	6
88	How the National Ambulatory Medical Care Survey has been used to identify health disparities in the care of patients in the United States. <i>Journal of the National Medical Association</i> , 2021, 113, 504-514.	0.8	4
89	Psoriasis Severity and Cardiometabolic Risk Factors in a Representative US National Study. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 719-730.	6.7	4
90	Lifelong Impact of Severe Atopic Dermatitis on Quality of Life: A Case Report. <i>Dermatology and Therapy</i> , 2021, 11, 1065-1070.	3.0	5

#	ARTICLE	IF	CITATIONS
91	Medication therapy management in dermatology: a call to action. <i>Journal of Dermatological Treatment</i> , 2021, 32, 373-375.	2.2	2
92	Confidence in Biosimilar Drugs is Not Much Improved by Framing Them as the “Gold” Alternative Treatment Option to Bio-originators. <i>Dermatology and Therapy</i> , 2021, 11, 1409-1413.	3.0	1
93	Development of an mHealth App for Patients With Psoriasis Undergoing Biological Treatment: Participatory Design Study. <i>JMIR Dermatology</i> , 2021, 4, e26673.	0.7	15
94	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2”Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1254-1268.	1.2	88
95	Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. <i>Clinics in Dermatology</i> , 2021, 39, 467-478.	1.6	9
96	Tildrakizumab: interpreting the data. <i>British Journal of Dermatology</i> , 2021, 185, 242-243.	1.5	0
97	The effect of physician appearance on patient perceptions of treatment plans. <i>Dermatology Online Journal</i> , 2021, 27, .	0.5	0
98	Clinical Characteristics and HealthCare Resource Utilization in Patients With Generalized Pustular Psoriasis: Real-World Evidence From a Large Claims-Based Dataset. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 151-158.	0.7	6
99	An overview of adapalene and benzoyl peroxide once-daily topical gel as a therapeutic option for acne. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1661-1667.	1.8	5
100	Virtual reality memory palace: An innovative dermatology education modality. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	4
101	Healthcare Resource Utilization and Baseline Characteristics of Patients With Generalized Pustular Psoriasis: Real-World Results From a Large US Database of Multiple Commercial Medical Insurers. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 143-150.	0.7	9
102	Association between menopausal hormone therapy and incidence of psoriasis: a secondary analysis from the Women’s Health Initiative randomized clinical trials. <i>British Journal of Dermatology</i> , 2021, 185, 669-671.	1.5	4
103	Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab. <i>Dermatology and Therapy</i> , 2021, 11, 1373-1384.	3.0	11
104	An mHealth App to Support Patients With Psoriasis in Relation to Follow-up Consultations: Qualitative Study. <i>JMIR Dermatology</i> , 2021, 4, e28882.	0.7	1
105	Studies of single and multiple institutions may illustrate different treatment practices for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, e51-e52.	1.2	0
106	How should medical students prepare for a clinical dermatology rotation?. <i>Dermatology Online Journal</i> , 2021, 27, .	0.5	0
107	Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 170-173.	0.7	1
108	Refractory Pediatric Psoriasis and Atopic Dermatitis: The Importance of Therapeutical Adherence and Biological Management. <i>Biomedicines</i> , 2021, 9, 958.	3.2	2

#	ARTICLE	IF	CITATIONS
109	Response to: "Successful implementation of phototherapy guidelines during the COVID-19 pandemic". Journal of the American Academy of Dermatology, 2021, 85, e321.	1.2	0
110	Impact of the COVID-19 pandemic on dermatology departments' support of medical students: A survey study. Dermatology Online Journal, 2021, 27, .	0.5	3
111	A wealth of new topicals for Atopic Dermatitis. Journal of Dermatological Treatment, 2021, 32, 575-575.	2.2	1
112	Diet-Related Phototoxic Reactions in Psoriatic Patients Undergoing Phototherapy: Results from a Multicenter Prospective Study. Nutrients, 2021, 13, 2934.	4.1	16
113	Morgellons disease etiology and therapeutic approach: a systematic review. Dermatology Online Journal, 2021, 27, .	0.5	3
114	Should atopic dermatitis patients starting JAK inhibitors take prophylactic acyclovir?. Journal of Dermatological Treatment, 2021, 32, 669-672.	2.2	4
115	Should the presence of psoriatic arthritis change how we manage psoriasis?. Journal of Dermatological Treatment, 2021, 32, 1-8.	2.2	2
116	Methotrexate for pityriasis lichenoides et varioliformis acuta (Mucha-Habermann disease) and pityriasis lichenoides chronica: a retrospective case series of 33 patients with an emphasis on outcomes. Journal of the American Academy of Dermatology, 2021, , .	1.2	2
117	Mycophenolate mofetil versus methotrexate for vulvar lichen planus: A 10-year retrospective cohort study demonstrates comparable efficacy and tolerability. Journal of the American Academy of Dermatology, 2021, , .	1.2	5
118	Dermatology COVID-19 Registries. Dermatologic Clinics, 2021, 39, 575-585.	1.7	12
119	New onset inflammatory bowel disease in patient treated with secukinumab: Case report and review of literature. Dermatologic Therapy, 2021, 34, e15151.	1.7	8
120	Long-term improvement of psoriasis patients' adherence to topical drugs: testing a patient-supporting intervention delivered by healthcare professionals. Trials, 2021, 22, 742.	1.6	10
121	Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study. BioDrugs, 2021, 35, 735-748.	4.6	13
122	Validation of the Self-Reported Psoriasis Treatment Convenience Scale (PTCS). Dermatology and Therapy, 2021, 11, 2077-2088.	3.0	7
123	Characterizing dermatology mobile applications that use artificial intelligence. Dermatology Online Journal, 2021, 27, .	0.5	2
124	The relative weak way and the absolute strong way to communicate risk information. Journal of Dermatological Treatment, 2021, , 1-3.	2.2	0
125	Real-world biologic and apremilast treatment patterns in patients with psoriasis and psoriatic arthritis. Dermatology Online Journal, 2021, 27, .	0.5	2
126	Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis. JAMA Dermatology, 2021, 157, 1306.	4.1	9

#	ARTICLE	IF	CITATIONS
127	Adherence to levetiracetam for management of epilepsy: Assessment with electronic monitors. Seizure: the Journal of the British Epilepsy Association, 2021, 93, 51-57.	2.0	2
128	Tumid lupus erythematosus and systemic lupus erythematosus: a rare coexistence. BMJ Case Reports, 2021, 14, e245196.	0.5	0
129	Understanding views of patients on biologics for psoriasis amid the COVID-19 pandemic. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e249-e251.	2.4	3
130	Anecdote Increases Patient Willingness to Take a Biologic Medication for Psoriasis. , 2021, 108, 20-24.		0
131	Secukinumab treatment and vaccination efficacy. Clinical and Experimental Dermatology, 2021, , .	1.3	0
132	Summary of Published Treatment Guidelines. , 2021, , 399-414.		0
133	Skin Disease in Children: Effects on Quality of Life, Stigmatization, Bullying, and Suicide Risk in Pediatric Acne, Atopic Dermatitis, and Psoriasis Patients. Children, 2021, 8, 1057.	1.5	34
134	The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications. International Journal of Molecular Sciences, 2021, 22, 12793.	4.1	50
135	Two cases of mycosis fungoides diagnosed after treatment non-response to dupilumab. Dermatology Online Journal, 2021, 27, .	0.5	3
136	Assessing the utility of the decoy effect on biologic treatment preference. Dermatology Online Journal, 2021, 27, .	0.5	0
137	Dermatologic management of ocular mucous membrane (cicatricial) pemphigoid with mycophenolate mofetil in 38 patients. Journal of the American Academy of Dermatology, 2021, , .	1.2	1
138	Utility of boron in dermatology. Journal of Dermatological Treatment, 2020, 31, 2-12.	2.2	5
139	Improving psoriasis patients's adherence to topical drugs: a systematic review. Journal of Dermatological Treatment, 2020, 31, 776-785.	2.2	14
140	Biologics monitoring: incongruity between recommendations and clinician monitoring trends. Journal of Dermatological Treatment, 2020, 31, 450-451.	2.2	1
141	Patients preferences for different corticosteroid vehicles are highly variable. Journal of Dermatological Treatment, 2020, 31, 147-151.	2.2	14
142	Hidradenitis suppurativa has an enormous impact on patients' lives. Journal of the American Academy of Dermatology, 2020, 82, 236-238.	1.2	7
143	Assessing the Effect of Clinical Trial Evidence and Anecdote on Caregivers's Willingness to Use Corticosteroids: A Randomized Controlled Trial. Journal of Cutaneous Medicine and Surgery, 2020, 24, 17-22.	1.2	7
144	Transcutaneous electrical nerve stimulation (TENS): a review of applications in dermatology. Journal of Dermatological Treatment, 2020, 31, 846-849.	2.2	7

#	ARTICLE	IF	CITATIONS
145	Sarecycline Review. <i>Annals of Pharmacotherapy</i> , 2020, 54, 164-170.	1.9	11
146	Assessing perceived adverse effects of biologic medications for patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 766-768.	1.2	1
147	Comparing psoriasis advertisement methods with patient willingness to initiate treatment. <i>Journal of Dermatological Treatment</i> , 2020, 31, 626-630.	2.2	2
148	Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis. <i>Annals of Pharmacotherapy</i> , 2020, 54, 380-387.	1.9	11
149	Optimizing presentation of expected treatment outcomes. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 602-604.	1.2	1
150	Dermatology Life Quality Index: does improving the instrument make it better?. <i>British Journal of Dermatology</i> , 2020, 182, 1082-1083.	1.5	1
151	Overcoming poor adherence is a major hurdle to managing atopic dermatitis. <i>British Journal of Dermatology</i> , 2020, 182, 836-837.	1.5	5
152	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. <i>Quality of Life Research</i> , 2020, 29, 369-380.	3.1	2
153	Our ambition in a changing landscape of psoriasis treatments. <i>Journal of Dermatological Treatment</i> , 2020, 31, 105-107.	2.2	0
154	Clinical recommendations made in dermatology publications are frequently not supported by adequate evidence. <i>Journal of Dermatological Treatment</i> , 2020, 32, 1-2.	2.2	2
155	An increasing trend in the number of publications and research projects among dermatology residency applicants. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 214-216.	1.2	15
156	Psoriasis causes as much disability as other major medical diseases. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 256-257.	1.2	21
157	Home UV Phototherapy. <i>Dermatologic Clinics</i> , 2020, 38, 109-126.	1.7	13
158	A handsâ€œoff approach may be more successful in treating chronic hand eczema. <i>British Journal of Dermatology</i> , 2020, 182, 1078-1078.	1.5	0
159	Commentary on Surgical Volume of Dermatologists Who Do Not Perform Mohs Micrographic Dermatologic Surgery. <i>Dermatologic Surgery</i> , 2020, 46, 7-8.	0.8	0
160	Assessing the Effect of Demographic Background on Barriers to Seek Medical Attention for Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 174-177.	0.7	0
161	Current and emerging biologics for the treatment of pediatric atopic dermatitis. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1435-1445.	3.1	6
162	A rare case of anal squamous cell carcinoma metastasizing to the scrotum. <i>JAAD Case Reports</i> , 2020, 6, 743-746.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Balancing rules with common sense in the protection of human subjects. Journal of Dermatological Treatment, 2020, 31, 661-661.	2.2	0
164	International collaboration. Journal of Dermatological Treatment, 2020, 31, 757-757.	2.2	1
165	<p>Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis</p>; ImmunoTargets and Therapy, 2020, Volume 9, 255-272.	5.8	30
166	An Analysis of the Perception of Psoriasis Symptoms and the Impact on Willingness to Seek Medical Attention. Journal of Psoriasis and Psoriatic Arthritis, 2020, 5, 109-113.	0.7	0
167	Steroid phobia isn't reduced by improving patients' knowledge of topical corticosteroids. Journal of the American Academy of Dermatology, 2020, 83, e403-e404.	1.2	11
168	Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report. , 2020, 8, e001073.		2
169	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. Journal of the American Academy of Dermatology, 2020, 83, 1704-1716.	1.2	43
170	Update on IL-17 Inhibitors for Psoriasis. Current Dermatology Reports, 2020, 9, 339-352.	2.1	2
171	A hyperkeratotic drug reaction in a patient on antiretroviral therapy. JAAD Case Reports, 2020, 6, 1239-1241.	0.8	0
172	Do increased risks of cancer mean we need to change our approach to treatment?. Journal of Dermatological Treatment, 2020, , 1-4.	2.2	0
173	Treatment Goals in Psoriasis: Which Outcomes Matter Most?. American Journal of Clinical Dermatology, 2020, 21, 505-511.	6.7	17
174	Trends in the Demographics and Treatment of Prurigo Nodularis in the United States. Journal of Cutaneous Medicine and Surgery, 2020, 24, 531-533.	1.2	0
175	New and Emerging Systemic Treatments for Atopic Dermatitis. Drugs, 2020, 80, 1041-1052.	10.9	76
176	International collaboration and rapid harmonization across dermatologic COVID-19 registries. Journal of the American Academy of Dermatology, 2020, 83, e261-e266.	1.2	13
177	Should patients stop their biologic treatment during the COVID-19 pandemic. Journal of Dermatological Treatment, 2020, 31, 317-318.	2.2	56
178	Emerging systemic drugs in the treatment of plaque psoriasis. Expert Opinion on Emerging Drugs, 2020, 25, 89-100.	2.4	23
179	An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis. Expert Opinion on Pharmacotherapy, 2020, 21, 1027-1033.	1.8	4
180	Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials. Annals of Pharmacotherapy, 2020, 54, 872-878.	1.9	4

#	ARTICLE	IF	CITATIONS
181	The bandwagon effect increases acne treatment willingness in teenagers. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1172-1174.	1.2	1
182	Pharmacological management of atopic dermatitis in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 761-771.	1.8	10
183	Efficacy of Applicator Devices for Self-Application of Topicals to the Back. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 249-252.	1.2	1
184	Medications in dermatology are safer and more efficient than they used to be. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 359-360.	2.4	0
185	Phototherapy: a Review and Update of Treatment Options in Dermatology. <i>Current Dermatology Reports</i> , 2020, 9, 10-21.	2.1	17
186	Placebo tailoring improves patient satisfaction of treatment plans in atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 944-946.	1.2	7
187	Dermatological disorders. , 2020, , 355-377.		0
188	A changed life: the life experiences of patients with psoriasis receiving biological treatment. <i>British Journal of Dermatology</i> , 2020, 183, 516-523.	1.5	17
189	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 839-846.	1.2	78
190	Methotrexate for the treatment of recalcitrant genital and extragenital lichen sclerosus: A retrospective series. <i>Dermatologic Therapy</i> , 2020, 33, e13473.	1.7	6
191	Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence. <i>Dermatology and Therapy</i> , 2020, 10, 351-364.	3.0	18
192	Framing atopic dermatitis topical medication application site discomfort as a signal of efficacy improves willingness to continue use. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1773-1775.	1.2	6
193	SECURE-Psoriasis: a de-identified registry of psoriasis patients diagnosed with COVID-19. <i>Journal of Dermatological Treatment</i> , 2020, 31, 327-327.	2.2	6
194	Efficacious psoriasis treatment improves patients' work productivity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e593-e596.	2.4	1
195	Evaluation of Accountability Measurement Tool in Patients with Psoriasis: A Validation Study. <i>Dermatology and Therapy</i> , 2020, 10, 495-502.	3.0	1
196	Recommendations for phototherapy during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 287-288.	1.2	31
197	Allergic Contact Dermatitis Secondary to Moisturizers. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 350-359.	1.2	3
198	Adherence in Atopic Dermatitis. <i>Updates in Clinical Dermatology</i> , 2020, , 75-84.	0.1	2

#	ARTICLE	IF	CITATIONS
199	Psychological Techniques to Promote Adherence. Updates in Clinical Dermatology, 2020, , 29-39.	0.1	1
200	Adherence in Psoriasis. Updates in Clinical Dermatology, 2020, , 59-74.	0.1	1
201	Real-World Effectiveness and Safety of Field- and Lesion-Directed Treatments for Actinic Keratosis. Journal of Drugs in Dermatology, 2020, 19, 756-762.	0.8	5
202	Why aren't they using their medicine?. Pediatric Dermatology, 2020, 37, 62-63.	0.9	0
203	Reasons for Nonadherence. Updates in Clinical Dermatology, 2020, , 1-11.	0.1	1
204	Adherence in Pediatric Populations. Updates in Clinical Dermatology, 2020, , 41-50.	0.1	0
205	Management of Residual Psoriasis in Patients on Biologic Treatment. Journal of Drugs in Dermatology, 2020, 19, 188-194.	0.8	2
206	Is Dupilumab an Immunosuppressant?. Journal of Drugs in Dermatology, 2020, 19, 209-210.	0.8	3
207	Utilization of an Online Cash-Pay Pharmacy for Topical 5-Fluorouracil Prescriptions in Older Patients. Journal of Drugs in Dermatology, 2020, 19, 539-542.	0.8	0
208	Demographics and the perception of psoriasis therapy adverse effects and treatment preference: A cross-sectional survey of a convenience sample of people with psoriasis. JAAD International, 2020, 1, 59-61.	2.2	0
209	Demographics and the perceived severity of psoriasis symptoms, effect on daily life, and willingness to seek medical attention. JAAD International, 2020, 1, 43-45.	2.2	2
210	Assessing the effect of demographic background on willingness to initiate a biologic. JAAD International, 2020, 1, 46-47.	2.2	0
211	Time Intervals Until the First Return Office Visit After New Medications. Journal of Drugs in Dermatology, 2020, 19, 1226-1230.	0.8	1
212	Adherence to topical treatment can improve treatment-resistant moderate psoriasis. Cutis, 2020, 105, 89-91;E2;E3.	0.3	2
213	Clinical case-viewing sessions in dermatology: the patient perspective. Cutis, 2020, 105, 200-201.	0.3	0
214	Publication rates on the topic of racial and ethnic diversity in dermatology versus other specialties. Dermatology Online Journal, 2020, 26, .	0.5	1
215	Safe Step Act: does it undermine step therapy?. Dermatology Online Journal, 2020, 26, .	0.5	0
216	Patients use more topical medication when the medications come in a larger container. Dermatology Online Journal, 2020, 26, .	0.5	0

#	ARTICLE	IF	CITATIONS
217	Advertising techniques increase biologic treatment willingness in patients with psoriasis. <i>Dermatology Online Journal</i> , 2020, 26, .	0.5	1
218	Digital future of dermatology. <i>Dermatology Online Journal</i> , 2020, 26, .	0.5	2
219	<i>Saccharomyces cerevisiae</i> as a skin physiology, pathology, and treatment model. <i>Dermatology Online Journal</i> , 2020, 26, .	0.5	0
220	Minimal clinically important difference (<scp>MCID</scp>) for work productivity and activity impairment (<scp>WPAI</scp>) questionnaire in psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 318-324.	2.4	26
221	Pilot study of the feasibility of a double-blind, randomized, placebo-controlled localized area ultraviolet phototherapy trial methodology. <i>Skin Research and Technology</i> , 2019, 25, 103-105.	1.6	0
222	Modulating Patient Perception of Systemic Psoriasis Treatment Risk. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 143-146.	0.7	0
223	Rates of psoriasis in patients with palmoplantar pustulosis. <i>British Journal of Dermatology</i> , 2019, 181, 887-888.	1.5	1
224	Microbiome, probiotics and dermatology. <i>British Journal of Dermatology</i> , 2019, 182, 8-9.	1.5	3
225	The complexity of adverse event assessment and counseling for patients on biologic treatment. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 809-811.	3.0	0
226	Assessing Efficacy and the Speed of Response in Psoriasis Treatment. <i>Journal of Dermatological Treatment</i> , 2019, 30, 523-524.	2.2	3
227	PBI34 PREDICTIVE VALUE OF EARLY PASI RESPONSE TO TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS. <i>Value in Health</i> , 2019, 22, S53.	0.3	1
228	PBI30 BUDGET-IMPACT AND COST-EFFECTIVENESS OF TILDRAKIZUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS FROM A US HEALTH PLAN PERSPECTIVE. <i>Value in Health</i> , 2019, 22, S52.	0.3	0
229	PBI38 TREATMENT PATTERNS OF BIOLOGICS AND APREMILAST AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS BY METABOLIC SYNDROME STATUS. <i>Value in Health</i> , 2019, 22, S54.	0.3	0
230	PBI41 TREATMENT PATTERNS OF BIOLOGICS AND APREMILAST AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS BY PSORIATIC ARTHRITIS STATUS. <i>Value in Health</i> , 2019, 22, S55.	0.3	0
231	<p>Accountability in patient adherence</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1511-1517.	1.8	8
232	Review of Outcome Measures in Trials and Practice for Psoriasis. <i>Current Dermatology Reports</i> , 2019, 8, 313-318.	2.1	1
233	Publication productivity of authors of psoriasis clinical practice guidelines with and without ties to industry. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1432-1433.	1.2	0
234	Topical and Oral Therapies for Childhood Atopic Dermatitis and Plaque Psoriasis. <i>Children</i> , 2019, 6, 125.	1.5	14

#	ARTICLE	IF	CITATIONS
235	Dermatology nurses view on factors related to Danish psoriasis patients' adherence to topical drugs: a focus group study. <i>Journal of Dermatological Treatment</i> , 2019, 32, 1-6.	2.2	2
236	Complementary and Integrative Therapies for Childhood Atopic Dermatitis. <i>Children</i> , 2019, 6, 121.	1.5	7
237	Update on Tildrakizumab for Psoriasis. <i>Current Dermatology Reports</i> , 2019, 8, 319-325.	2.1	1
238	A new spin on improving adherence. <i>Journal of Dermatological Treatment</i> , 2019, 30, 631-632.	2.2	3
239	Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis. <i>Children</i> , 2019, 6, 103.	1.5	18
240	Treatment decisions in psoriasis. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 947-949.	1.4	2
241	The role of veterinarians in assisting clients identify and care for emotional support animals. <i>Journal of the American Veterinary Medical Association</i> , 2019, 254, 199-202.	0.5	5
242	Tolerability of Topical Treatments for Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2019, 9, 71-102.	3.0	21
243	Rosacea: Relative risk versus absolute risk of malignant comorbidities. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 623-624.	1.2	5
244	Topical Retinoids in Acne Vulgaris: A Systematic Review. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 345-365.	6.7	71
245	Mechanisms of microbial pathogenesis and the role of the skin microbiome in psoriasis: A review. <i>Clinics in Dermatology</i> , 2019, 37, 160-166.	1.6	54
246	An Evidence-Based Evaluation of Disclosure. <i>Journal of Dermatological Treatment</i> , 2019, 30, 423-423.	2.2	0
247	Lead with your gut: research-implicated infant gut staphylococcal strains may predict development of atopic dermatitis. <i>British Journal of Dermatology</i> , 2019, 180, 1296-1297.	1.5	1
248	Tracking the price of existing biologics when drugs enter the market. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 375-377.	1.4	11
249	<p>Treatment-resistant prurigo nodularis</p>. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2019, Volume 12, 345-346.	1.8	1
250	The most common causes of burnout among US academic dermatologists based on a survey study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 269-270.	1.2	32
251	Depression in hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2019, 181, 1087-1088.	1.5	6
252	Treatment patterns and costs among biologic-naïve patients initiating apremilast or biologics for psoriatic arthritis. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 699-709.	1.4	7

#	ARTICLE	IF	CITATIONS
253	A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 102-110.	1.2	52
254	Can We Tell Patients That IL-23 and TNF- α Inhibition Are “Natural” Ways to Treat Psoriasis?. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 337-338.	1.2	0
255	Evaluating Costs of Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 133-142.	0.7	2
256	Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1650-1657.	1.2	20
257	Evaluating crisaborole as a treatment option for atopic dermatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1057-1063.	1.8	5
258	A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 523-536.	2.4	9
259	Even mild hidradenitis suppurativa impairs quality of life. <i>British Journal of Dermatology</i> , 2019, 181, 838-839.	1.5	9
260	Regardless of how risks are framed, patients seem hesitant to use topical steroids for atopic dermatitis. <i>British Journal of Dermatology</i> , 2019, 181, 842-844.	1.5	8
261	The Decoy Effect. <i>Journal of Dermatological Treatment</i> , 2019, 30, 1-1.	2.2	6
262	Validation of a Hidradenitis Suppurativa Self-Assessment Tool. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 388-390.	1.2	15
263	Choice Overload in Systemic Psoriasis Therapy. <i>Journal of Dermatological Treatment</i> , 2019, 30, 103-104.	2.2	0
264	Sociodemographic factors do not have a large influence on adherence to topical treatment in patients with psoriasis. <i>British Journal of Dermatology</i> , 2019, 181, 381-382.	1.5	3
265	Engagement can increase patient willingness to take medications. <i>British Journal of Dermatology</i> , 2019, 181, 408-409.	1.5	1
266	Differences in healthcare barriers based on racial and/or ethnic background for patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2019, 32, 1-5.	2.2	14
267	Asymptomatic Crohn’s disease identified in a patient being treated with secukinumab: A case report. <i>SAGE Open Medical Case Reports</i> , 2019, 7, 2050313X1989358.	0.3	7
268	Assessment of Provider Utilization Through Skin Biopsy Rates. <i>Dermatologic Surgery</i> , 2019, 45, 1035-1041.	0.8	6
269	Emotional Well-Being Is Impaired in Hidradenitis Suppurativa Patients. <i>Skin Appendage Disorders</i> , 2019, 5, 366-369.	1.0	3
270	Manipulating mindsets to improve patient outcomes: is it ethical? Can it be avoided?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e79-e81.	2.4	2

#	ARTICLE	IF	CITATIONS
271	Psoriasis and Atopic Dermatitis –Resistant–to Topical Treatment Responds Rapidly to Topical Desoximetasone Spray. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 157-163.	1.2	3
272	Health Care Utilization and Cost Associated with Biologic Treatment Patterns Among Patients with Moderate to Severe Psoriasis: Analyses from a Large U.S. Claims Database. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 479-488.	0.9	39
273	Review of future insights of Dragon's Blood in dermatology. <i>Dermatologic Therapy</i> , 2019, 32, e12786.	1.7	10
274	Pharmacotherapeutic strategies for standard treatment-resistant psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 443-454.	1.8	14
275	An update on the topical and oral therapy options for treating pediatric atopic dermatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 621-629.	1.8	12
276	The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment. <i>Journal of Dermatological Treatment</i> , 2019, 30, 446-453.	2.2	9
277	Real-world US healthcare costs of psoriasis for biologic-naïve patients initiating apremilast or biologics. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 45-54.	1.4	14
278	Rosacea Severity Assessment: Review of Evaluation Methods Used in Clinical Trials. , 2019, , 1-14.		0
279	Clinical effectiveness of novel rosacea therapies. <i>Current Opinion in Pharmacology</i> , 2019, 46, 14-18.	3.5	16
280	Tildrakizumab: A Review of Phase II and III Clinical Trials. <i>Annals of Pharmacotherapy</i> , 2019, 53, 413-418.	1.9	18
281	Use of absolute risk measurements in observational dermatology studies: important information for decision-making is frequently absent. <i>British Journal of Dermatology</i> , 2019, 180, 678-679.	1.5	0
282	Treatment patterns among patients with psoriasis using a large national payer database in the United States: a retrospective study. <i>Journal of Medical Economics</i> , 2019, 22, 53-62.	2.1	5
283	Pharmacy costs of systemic medications for hidradenitis suppurativa in the United States. <i>Journal of Dermatological Treatment</i> , 2019, 30, 519-521.	2.2	6
284	Relative efficacy of systemic treatments for atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 411-416.e4.	1.2	30
285	Heterogeneity and variation of innovator biologics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e161-e163.	2.4	0
286	Caregiver willingness to treat atopic dermatitis is not much improved by anchoring. <i>Journal of Dermatological Treatment</i> , 2019, 30, 471-474.	2.2	4
287	The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab. <i>American Health and Drug Benefits</i> , 2019, 12, 22-26.	0.5	0
288	The Challenge of Managing Atopic Dermatitis in the United States. <i>American Health and Drug Benefits</i> , 2019, 12, 83-93.	0.5	21

#	ARTICLE	IF	CITATIONS
289	Photodamage spares the distal digits owing to primate-like hand flexion. <i>Dermatology Online Journal</i> , 2019, 25, .	0.5	0
290	The Treatment of Primary Focal Hyperhidrosis. <i>Skin Therapy Letter</i> , 2019, 24, 1-7.	0.3	6
291	Cutaneous manifestations of genodermatoses and primary immunodeficiency. <i>Dermatology Online Journal</i> , 2019, 25, .	0.5	1
292	A smartphone application supporting patients with psoriasis improves adherence to topical treatment: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2018, 179, 1062-1071.	1.5	61
293	Is depression screening in patients with acne critical?. <i>British Journal of Dermatology</i> , 2018, 179, 226-227.	1.5	2
294	Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. <i>Journal of Dermatological Treatment</i> , 2018, 29, 769-774.	2.2	29
295	Web App and Text Message-Based Patient Education in Mohs Micrographic Surgery: A Randomized Controlled Trial. <i>Dermatologic Surgery</i> , 2018, 44, 924-932.	0.8	32
296	It may not be time to clean out the sample closets. <i>Journal of Dermatological Treatment</i> , 2018, 29, 1-2.	2.2	1
297	In-office compounding of lidocaine-epinephrine: An option for anesthesia preparation before skin biopsy. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 159-160.	1.2	4
298	A Review and Update of Phototherapy Treatment Options for Psoriasis. <i>Current Dermatology Reports</i> , 2018, 7, 43-51.	2.1	3
299	The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans. <i>Journal of Medical Economics</i> , 2018, 21, 537-541.	2.1	3
300	Insights into future therapeutics for atopic dermatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 265-278.	1.8	9
301	Yet another step forward!. <i>British Journal of Dermatology</i> , 2018, 178, 22-22.	1.5	0
302	Validity and Reliability of a Rosacea Self-Assessment Tool. <i>Dermatologic Clinics</i> , 2018, 36, 93-96.	1.7	3
303	Measurement of Disease Severity in a Population of Rosacea Patients. <i>Dermatologic Clinics</i> , 2018, 36, 97-102.	1.7	3
304	Rosacea Triggers. <i>Dermatologic Clinics</i> , 2018, 36, 123-126.	1.7	17
305	A Review of the Current Modalities for the Treatment of Papulopustular Rosacea. <i>Dermatologic Clinics</i> , 2018, 36, 135-150.	1.7	15
306	Medical Management of Facial Redness in Rosacea. <i>Dermatologic Clinics</i> , 2018, 36, 151-159.	1.7	13

#	ARTICLE	IF	CITATIONS
307	Patient Costs Associated with Rosacea. <i>Dermatologic Clinics</i> , 2018, 36, 167-170.	1.7	1
308	Coping Mechanisms and Resources for Patients Suffering from Rosacea. <i>Dermatologic Clinics</i> , 2018, 36, 171-174.	1.7	13
309	Complexities of Rosacea. <i>Dermatologic Clinics</i> , 2018, 36, xiii.	1.7	1
310	An assessment of the use of antihistamines in the management of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 92-96.	1.2	54
311	Adherence to biologics in patients with psoriasis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 155-161.	3.0	14
312	Comment on "Serious infections among a large cohort of subjects with systemically treated psoriasis". <i>Journal of the American Academy of Dermatology</i> , 2018, 78, e113-e114.	1.2	2
313	Rapid, successful treatment of atopic dermatitis recalcitrant to topical corticosteroids. <i>Pediatric Dermatology</i> , 2018, 35, 278-279.	0.9	2
314	Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know. <i>American Journal of the Medical Sciences</i> , 2018, 355, 411-417.	1.1	8
315	Compliance and Persistency. , 2018, , 37-49.		0
316	Ivermectin 1% (CD5024) for the treatment of rosacea. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 511-516.	1.8	19
317	Desoximetasone 0.25% spray, adrenal suppression and efficacy in extensive plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 36-38.	2.2	2
318	The efficacy of short-term clobetasol lotion in the treatment of scalp psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 111-115.	2.2	5
319	Topical 0.25% desoximetasone spray efficacy for moderate to severe plaque psoriasis: a randomized clinical trial. <i>Journal of Dermatological Treatment</i> , 2018, 29, 32-35.	2.2	2
320	Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. <i>Journal of Dermatological Treatment</i> , 2018, 29, 13-18.	2.2	127
321	Epidemiology of mental health comorbidity in psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 487-495.	2.2	59
322	The safety of treatments used in pyoderma gangrenosum. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 55-61.	2.4	11
323	Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study. <i>British Journal of Dermatology</i> , 2018, 178, e215-e216.	1.5	26
324	Most common dermatology diagnoses to the emergency department in the paediatric population. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e144-e146.	2.4	3

#	ARTICLE	IF	CITATIONS
325	Applying behavioural economics to psoriasis treatment: interventions to improve patient adherence to biologics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e65-e66.	2.4	3
326	A safety review of the medications used to treat atopic dermatitis. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 179-183.	2.4	2
327	4-Day evaluation of the irritation potential of topical desoximetasone 0.25% and 0.05% spray on light-exposed skin. <i>Journal of Dermatological Treatment</i> , 2018, 29, 415-417.	2.2	0
328	Six week evaluation of the potential for topical desoximetasone 0.25% spray to induce photoallergic skin reaction. <i>Journal of Dermatological Treatment</i> , 2018, 29, 269-271.	2.2	0
329	Chronic mucocutaneous candidiasis: what can we conclude about IL-17 antagonism?. <i>Journal of Dermatological Treatment</i> , 2018, 29, 475-480.	2.2	3
330	Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials. <i>Annals of Pharmacotherapy</i> , 2018, 52, 380-387.	1.9	9
331	Prescriptions for atopic dermatitis: oral corticosteroids remain commonplace. <i>Journal of Dermatological Treatment</i> , 2018, 29, 238-240.	2.2	20
332	Treatment Changes in Patients With Moderate to Severe Psoriasis: A Retrospective Chart Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 25-30.	1.2	7
333	PSS68 - THE MOST INFLUENTIAL DRIVERS OF PSORIASIS PATIENTS'™ TREATMENT CHOICE: A DISCRETE CHOICE EXPERIMENT SURVEY IN THE US. <i>Value in Health</i> , 2018, 21, S434-S435.	0.3	1
334	Public Perception of Ethical Issues in Dermatology: Evidenced by New York Times Commenters. <i>Dermatologic Surgery</i> , 2018, 44, 1571-1577.	0.8	2
335	Effectiveness of the Tacrolimus Swish-and-Spit Treatment Regimen in Patients With Geographic Tongue. <i>JAMA Dermatology</i> , 2018, 154, 1481.	4.1	8
336	Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1209-1218.	3.1	18
337	Investigational drugs in phase II clinical trials for moderate to severe plaque psoriasis - potential new treatments on the horizon. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 931-939.	4.1	1
338	Satisfied patients and pediatricians: a cross-sectional analysis. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 299-307.	1.2	2
339	Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families. <i>Dermatology and Therapy</i> , 2018, 8, 605-619.	3.0	18
340	Current Psoriasis Efficacy Outcome Measures in Clinical Trials. <i>Current Dermatology Reports</i> , 2018, 7, 261-268.	2.1	2
341	Biologics are too complicated to duplicate: should we be worried about biosimilars?. <i>British Journal of Dermatology</i> , 2018, 179, 557-558.	1.5	5
342	Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1489-1497.	2.0	13

#	ARTICLE	IF	CITATIONS
343	Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1483-1503.	1.8	109
344	The perceived promise of p19 inhibitors. <i>British Journal of Dermatology</i> , 2018, 179, 556-557.	1.5	2
345	Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 821-838.	6.7	159
346	A Pilot Study Characterizing Factors in Adherence to Cutaneous Lupus Treatment. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 530-532.	1.2	0
347	Benzoyl peroxide gel stains synthetic fabrics less than they stain cotton. <i>Journal of the American Academy of Dermatology</i> , 2018, 85, 481-482.	1.2	2
348	Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2018, 154, 903.	4.1	75
349	Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 617-622.	0.9	16
350	Risankizumab for psoriasis. <i>Lancet</i> , The, 2018, 392, 616-617.	13.7	4
351	Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States. <i>Dermatology and Therapy</i> , 2018, 8, 441-453.	3.0	5
352	Future Therapeutics in Psoriasis. <i>Updates in Clinical Dermatology</i> , 2018, , 93-112.	0.1	1
353	Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2494-2500.	1.9	120
354	Patient Perceptions of Hidradenitis Suppurativa Stressors. <i>Journal of Dermatological Treatment</i> , 2018, 29, 429-430.	2.2	2
355	Atopic dermatitis: a look into systemic treatments and adherence considerations. <i>Journal of Dermatological Treatment</i> , 2018, 29, 535-535.	2.2	2
356	Pharmacokinetics of tazarotene and acitretin in psoriasis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 919-927.	3.3	27
357	Adherence and resource use among psoriasis patients treated with biologics. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 609-617.	1.4	16
358	Psoriasis in Skin of Color. , 2018, , 241-250.		0
359	Barriers to treatment: describing them from a different perspective. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 129-133.	1.8	44
360	Current treatment options for acanthosis nigricans. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2018, Volume 11, 407-413.	1.8	32

#	ARTICLE	IF	CITATIONS
361	Hidradenitis and smoking. <i>British Journal of Dermatology</i> , 2018, 178, 810-811.	1.5	5
362	Quality of Life in Individuals with Erythematotelangiectatic and Papulopustular Rosacea: Findings From a Web-based Survey. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2018, 11, 47-52.	0.1	14
363	ProvenCare-Psoriasis: A disease management model to optimize care. <i>Dermatology Online Journal</i> , 2018, 24, .	0.5	1
364	Hyperpigmented Patches on the Dorsal Hands. <i>American Family Physician</i> , 2018, 97, 603-604.	0.1	0
365	Screening for depression in rosacea patients. <i>Cutis</i> , 2018, 102, 36-38.	0.3	6
366	Addressing public criticism: a potential HIPAA violation. <i>Dermatology Online Journal</i> , 2018, 24, .	0.5	1
367	Topical corticosteroids for treatment-resistant atopic dermatitis. <i>Cutis</i> , 2018, 102, 205-209.	0.3	3
368	Psychosocial impact of psoriasis: a review for dermatology residents. <i>Cutis</i> , 2018, 102, 21-25.	0.3	19
369	Automobile injury: a common familiar risk for presenting and comparing risks in dermatology. <i>Cutis</i> , 2018, 102, 416-420.	0.3	0
370	Strategies to reduce youth indoor tanning injuries. <i>Cutis</i> , 2018, 102, 383-384.	0.3	0
371	Incidence rates of comorbidities among patients with psoriasis in the United States. <i>Dermatology Online Journal</i> , 2018, 24, .	0.5	6
372	Morgellons disease: insights into treatment. <i>Dermatology Online Journal</i> , 2018, 24, .	0.5	1
373	Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review. <i>Dermatology Online Journal</i> , 2018, 24, .	0.5	3
374	Adherence in dermatology. <i>Journal of Dermatological Treatment</i> , 2017, 28, 94-103.	2.2	49
375	Variation in cash price of the generic medications most prescribed by dermatologists in pharmacies across the United States. <i>Journal of Dermatological Treatment</i> , 2017, 28, 119-128.	2.2	5
376	Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. <i>Journal of Dermatological Treatment</i> , 2017, 28, 591-599.	2.2	48
377	Chemical pharmacotherapy options for managing adult acne. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 263-273.	1.8	10
378	Increasing Adherence with Topical Agents for Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 323-332.	6.7	44

#	ARTICLE	IF	CITATIONS
379	Treatment Adherence Intervention Studies in Dermatology and Guidance on How to Support Adherence. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 253-271.	6.7	49
380	Risk versus benefit or risk versus risk: Risk aversion in the medical decision making process. <i>Journal of Dermatological Treatment</i> , 2017, 28, 1-2.	2.2	6
381	Nasal Valve Reconstruction Using a Titanium Implant: An Outcomes Study. <i>Craniofacial Trauma & Reconstruction</i> , 2017, 10, 175-182.	1.3	5
382	Psoriasis, Depression, and Inflammatory Overlap: A Review. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 613-620.	6.7	59
383	Evolution in psoriasis management. <i>Journal of Dermatological Treatment</i> , 2017, 28, 187-187.	2.2	0
384	Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database. <i>BMC Health Services Research</i> , 2017, 17, 337.	2.2	41
385	Physicians Report Sleep Apnea Infrequently in Older and Older Vulnerable Adults. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 2023-2028.	2.6	7
386	Dupilumab for atopic dermatitis. <i>Lancet</i> , The, 2017, 389, 2265-2266.	13.7	15
387	TNF Inhibitors for Psoriasis and Psoriatic Arthritis. <i>Current Dermatology Reports</i> , 2017, 6, 113-120.	2.1	1
388	Real-world burden of comorbidities in US patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 287-292.e4.	1.2	68
389	Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. <i>Journal of Medical Economics</i> , 2017, 20, 982-990.	2.1	33
390	Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs. <i>Journal of Medical Economics</i> , 2017, 20, 1000-1006.	2.1	7
391	An Anchoring-Based Intervention to Increase Patient Willingness to Use Injectable Medication in Psoriasis. <i>JAMA Dermatology</i> , 2017, 153, 932.	4.1	21
392	Comorbidities in patients with psoriasis: The role of the dermatologist. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 191-192.	1.2	6
393	Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 70-85.	4.7	7
394	Relative versus absolute risk of comorbidities in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 531-537.	1.2	20
395	Reply to: "œls treatment of acne as simple as encouraging primary care physicians to prescribe more retinoids?" <i>Journal of the American Academy of Dermatology</i> , 2017, 76, e39.	1.2	0
396	Adherence in Atopic Dermatitis. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1027, 139-159.	1.6	38

#	ARTICLE	IF	CITATIONS
397	Implications of treatment resistant severe psoriasis for benchmarking quality of care. <i>Journal of Dermatological Treatment</i> , 2017, 28, 475-475.	2.2	0
398	Oxymetazoline hydrochloride cream for facial erythema associated with rosacea. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1049-1054.	3.1	20
399	A Review of the Use of Secukinumab for Psoriatic Arthritis. <i>Rheumatology and Therapy</i> , 2017, 4, 233-246.	2.3	20
400	Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 716-721.	2.2	22
401	Perspectives. <i>Journal of Dermatological Treatment</i> , 2017, 28, 373-373.	2.2	1
402	Advances in treating psoriasis in the elderly with small molecule inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1965-1973.	1.8	14
403	Rethinking the costs of psoriasis management. <i>Journal of Dermatological Treatment</i> , 2017, 28, 573-573.	2.2	0
404	Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update. <i>Pharmacoeconomics</i> , 2017, 35, 177-190.	3.3	13
405	Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 200-205.	2.2	12
406	Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 498-506.	2.4	28
407	Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. <i>British Journal of Dermatology</i> , 2017, 176, 759-764.	1.5	65
408	Participating in trials can inform better clinical practice. <i>British Journal of Dermatology</i> , 2017, 177, 1148-1149.	1.5	1
409	Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2017, Volume 10, 385-391.	1.8	10
410	Accountability: a missing construct in models of adherence behavior and in clinical practice. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1285-1294.	1.8	45
411	Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 583-589.	0.9	9
412	Advances in Psoriasis. <i>Southern Medical Journal</i> , 2017, 110, 65-75.	0.7	10
413	Severe and acute complications of biologics in psoriasis. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 586-596.	0.2	4
414	Cost of diagnosing psoriasis and rosacea for dermatologists versus primary care physicians. <i>Cutis</i> , 2017, 99, 134-136.	0.3	0

#	ARTICLE	IF	CITATIONS
415	Characterization of Patients' Quality of Life and Experience in the Course of Acne Treatment. <i>Skinmed</i> , 2017, 15, 431-435.	0.0	2
416	Ultraviolet B Phototherapy. , 2016, , 17-25.		0
417	Cost-Effectiveness of Ivermectin 1% Cream in Adults with Papulopustular Rosacea in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 654-665.	0.9	9
418	Ethical considerations in adherence research. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2429-2435.	1.8	13
419	Apremilast. , 2016, , 75-82.		0
420	A Review of Localized Office and Home Devices in the Treatment of Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016, 2, 22-30.	0.7	1
421	New developments in the treatment of rosacea – role of once-daily ivermectin cream. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2016, 9, 71.	1.8	36
422	Interventions to increase adherence to acne treatment. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2091-2096.	1.8	35
423	Treatment of Molluscum Contagiosum with Imiquimod in the United States: A Retrospective Cross-sectional Study. <i>Pediatric Dermatology</i> , 2016, 33, 227-228.	0.9	3
424	Reply to: "Comment on "Review of patient registries in dermatology"â€™â€œ. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, e243.	1.2	1
425	Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. <i>BMC Dermatology</i> , 2016, 16, 15.	2.1	77
426	Review of maintenance of response to psoriasis treatments. <i>Journal of Dermatological Treatment</i> , 2016, 27, 293-297.	2.2	11
427	Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 789-797.	3.1	9
428	Review of patient registries in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 824-829.	1.2	19
429	Current challenges and emerging drug delivery strategies for the treatment of psoriasis. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1461-1473.	5.0	31
430	Use of topical retinoids by dermatologists and non-dermatologists in the management of acne vulgaris. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1252-1254.	1.2	18
431	Recognition of Sleep Apnea Is Increasing. Analysis of Trends in Two Large, Representative Databases of Outpatient Practice. <i>Annals of the American Thoracic Society</i> , 2016, 13, 2027-2034.	3.2	19
432	Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1162-1170.e3.	1.2	57

#	ARTICLE	IF	CITATIONS
433	Cardiovascular Disease Outcomes Associated with Three Major Inflammatory Dermatologic Diseases: A Propensity-Matched Case Control Study. <i>Dermatology and Therapy</i> , 2016, 6, 649-658.	3.0	31
434	Phototherapy in Scleroderma. <i>Dermatology and Therapy</i> , 2016, 6, 519-553.	3.0	20
435	Advances in and hope for the treatment of parasitosis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 197-197.	2.2	1
436	Rosacea Management. <i>Skin Appendage Disorders</i> , 2016, 2, 26-34.	1.0	55
437	The proliferation of online for-profit medical journals. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 656-657.	1.2	2
438	The most common dermatology diagnoses in the emergency department. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1261-1262.	1.2	8
439	Adherence to topical treatments for actinic keratosis. <i>British Journal of Dermatology</i> , 2016, 175, 872-872.	1.5	1
440	Rosacea patients seeking advice: Qualitative analysis of patients'™ posts on a rosacea support forum. <i>Journal of Dermatological Treatment</i> , 2016, 27, 99-102.	2.2	22
441	Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. <i>Drug Safety</i> , 2016, 39, 755-762.	3.2	112
442	Current status and future prospects for biologic treatments of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1273-1287.	3.0	19
443	Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: The Psoriasis Symptoms and Signs Diary. <i>Journal of Dermatology & Dermatologic Surgery</i> , 2016, 20, 19-26.	0.2	23
444	Impact and management of depression in psoriasis patients. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 147-152.	1.8	33
445	Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary. <i>Journal of Dermatological Treatment</i> , 2016, 27, 322-327.	2.2	30
446	The cost of applying to dermatology residency. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 775-776.	1.2	8
447	Online Reviews of Physicians'™Reply. <i>JAMA Dermatology</i> , 2016, 152, 350.	4.1	0
448	Online Reviews of Physicians. <i>JAMA Dermatology</i> , 2016, 152, 143.	4.1	5
449	Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 525-539.	3.1	2
450	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 841-850.	1.2	135

#	ARTICLE	IF	CITATIONS
451	Tazarotene foam, 0.1%, for the treatment of acne. Expert Opinion on Drug Safety, 2016, 15, 99-103.	2.4	13
452	Ultraviolet phototherapy for cutaneous diseases: a concise review. Oral Diseases, 2016, 22, 253-259.	3.0	62
453	Erythrodermic psoriasis and severe hypotension requiring intensive care unit hospitalization: Poor treatment outcome as a result of poor adherence. Journal of Dermatological Treatment, 2016, 27, 134-135.	2.2	3
454	Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. Journal of Dermatological Treatment, 2016, 27, 224-227.	2.2	24
455	Measuring Adherence in Clinical Trials. , 2016, , 53-59.		1
456	Cutaneous cryosurgery in the United States. Journal of Dermatological Treatment, 2016, 27, 91-4.	2.2	5
457	Relative Importance of Mode of Administration in Treatment Preferences among Plaque Psoriasis Patients in the United States. Journal of Health Economics and Outcomes Research, 2016, 4, 141-157.	1.2	10
458	Adherence in Acne. , 2016, , 77-99.		0
459	Optimizing the Physician-Patient Relationship and Educating the Patient About Adherence. , 2016, , 143-150.		0
460	Choosing the Treatment the Patient Is Most Likely To Use. , 2016, , 151-162.		0
461	The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives. American Health and Drug Benefits, 2016, 9, 504-513.	0.5	58
462	Costs of Common Psoriasis Medications, 2010-2014. Journal of Drugs in Dermatology, 2016, 15, 305-8.	0.8	3
463	Increasing adherence to topical therapy in psoriasis through use of solution medication. Dermatology Online Journal, 2016, 22, .	0.5	2
464	First-Line Fixed-Combination Psoriasis Treatment Is Associated With Lower Healthcare Costs. Skinmed, 2016, 14, 266-272.	0.0	1
465	A boxed warning for inadequate psoriasis treatment. Cutis, 2016, 98, 206-207.	0.3	0
466	Presenting treatment safety data: subjective interpretations of objective information. Cutis, 2016, 98, 259-262.	0.3	1
467	Hypothyroidism in Patients with Psoriasis or Rosacea: A Large Population Study. Dermatology Online Journal, 2016, 22, .	0.5	0
468	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. British Journal of Dermatology, 2015, 173, 949-961.	1.5	253

#	ARTICLE	IF	CITATIONS
469	DERM: Dermatologic Education Reinforced Mnemonically. Journal of Dermatological Treatment, 2015, 26, 491-492.	2.2	0
470	Acne vulgaris. Nature Reviews Disease Primers, 2015, 1, 15029.	30.5	258
471	How to manage the mother of all treatment refusal. Journal of Dermatological Treatment, 2015, 26, 395-395.	2.2	0
472	Primary Nonadherence in Acne Treatmentâ€”Reply. JAMA Dermatology, 2015, 151, 1145.	4.1	0
473	Training for prescribing inâ€”office and home phototherapy. Photodermatology Photoimmunology and Photomedicine, 2015, 31, 325-332.	1.5	8
474	Pharmacological treatments in pregnant women with psoriasis in the U.S.A.. British Journal of Dermatology, 2015, 172, 807-810.	1.5	2
475	Internet-based adherence interventions for treatment of chronic disorders in adolescents. Adolescent Health, Medicine and Therapeutics, 2015, 6, 91.	0.9	8
476	Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 874-888.	0.9	46
477	Clinical potential of brodalumab in the management of psoriasis: the evidence to date. Psoriasis: Targets and Therapy, 2015, 5, 35.	2.2	0
478	Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 201-209.	0.9	55
479	Interventions to Increase Treatment Adherence in Pediatric Atopic Dermatitis: A Systematic Review. Journal of Clinical Medicine, 2015, 4, 231-242.	2.4	57
480	Frequency of Primary Nonadherence to Acne Treatment. JAMA Dermatology, 2015, 151, 623.	4.1	53
481	Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized. Dermatology and Therapy, 2015, 5, 91-105.	3.0	13
482	The 5-point Investigatorâ€™s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. Journal of Dermatological Treatment, 2015, 26, 23-31.	2.2	173
483	Hidradenitis Suppurativa Management in the United States: An Analysis of the National Ambulatory Medical Care Survey and MarketScan Medicaid Databases. Skin Appendage Disorders, 2015, 1, 65-73.	1.0	24
484	Effect of frequency on entrance and propagation pattern of highâ€”frequency (radiofrequency) electrical currents in biologic tissues. Skin Research and Technology, 2015, 21, 291-294.	1.6	0
485	To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2015, 73, 420-428.e1.	1.2	32
486	Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012. JAMA Dermatology, 2015, 151, 1081.	4.1	1,290

#	ARTICLE	IF	CITATIONS
487	Tolerability of Topical Retinoids. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 530-538.	1.2	26
488	Biologics and biosimilars. <i>Journal of Dermatological Treatment</i> , 2015, 26, 299-302.	2.2	31
489	Psoriasis during pregnancy: characteristics and important management recommendations. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 709-720.	3.0	28
490	Immunogenicity of Biologic Treatments for Psoriasis: Therapeutic Consequences and the Potential Value of Concomitant Methotrexate. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 285-294.	6.7	41
491	Assessment of rosacea severity: A review of evaluation methods used in clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 138-143.e4.	1.2	30
492	Interleukin 17 deficiency and implications in cutaneous and systemic diseases. <i>Journal of Dermatology & Dermatologic Surgery</i> , 2015, 19, 73-79.	0.2	10
493	Inflammatory diseases: Integrating biosimilars into clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, S16-S21.	3.4	22
494	Trends in Mohs Surgery From 1995 to 2010. <i>Dermatologic Surgery</i> , 2015, 41, 397-403.	0.8	29
495	A guide to prescribing home phototherapy for patients with psoriasis: The appropriate patient, the type of unit, the treatment regimen, and the potential obstacles. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 868-878.e1.	1.2	32
496	A Review of the Use of Tanning Beds as a Dermatological Treatment. <i>Dermatology and Therapy</i> , 2015, 5, 37-51.	3.0	19
497	A Review of Patient Lifting Interventions to Reduce Health Care Worker Injuries. <i>Workplace Health and Safety</i> , 2015, 63, 267-275.	1.4	23
498	Quality of Life of Patients With Pyoderma Gangrenosum and Hidradenitis Suppurativa. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 391-396.	1.2	17
499	The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 877-884.	1.4	6
500	Modifying a 30-gauge needle as a hook for hard-to-access biopsy sites. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e183-e184.	1.2	0
501	How often do pharmacology textbooks address medication adherence?. <i>Journal of Dermatological Treatment</i> , 2015, 26, 199-201.	2.2	0
502	Oral tofacitinib for psoriasis: what happens with interrupted treatment?. <i>British Journal of Dermatology</i> , 2015, 172, 1194-1195.	1.5	2
503	Dupilumab for the treatment of atopic dermatitis: A clinical trial review. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1657-1660.	3.1	10
504	Translating Atopic Dermatitis Management Guidelines Into Practice for Primary Care Providers. <i>Pediatrics</i> , 2015, 136, 554-565.	2.1	78

#	ARTICLE	IF	CITATIONS
505	Trends in Ambulatory Health Care Usage for Adult Acne. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 377-379.	1.2	2
506	Obtaining an Adequate Specimen for the Diagnosis of Pigmented Lesions. <i>Journal of the American Board of Family Medicine</i> , 2015, 28, 523-525.	1.5	2
507	Reasons for Treatment Changes in Patients With Moderate to Severe Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 361-366.	1.2	7
508	Emerging drugs for the treatment of acne. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 91-101.	2.4	40
509	Economic and Comorbidity Burden Among Moderate-to-Severe Psoriasis Patients with Comorbid Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 708-717.	3.4	53
510	The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. <i>British Journal of Dermatology</i> , 2015, 172, 1487-1497.	1.5	91
511	Improved psoriasis with weight loss: the role of behavioural factors. <i>British Journal of Dermatology</i> , 2015, 172, 826-827.	1.5	2
512	Moving Away from Fee-for-Service: Implications for Medication Adherence. <i>Southern Medical Journal</i> , 2015, 108, 298-299.	0.7	0
513	Rosacea Patient Perspectives on Homeopathic and Over-the-counter Therapies. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2015, 8, 30-4.	0.1	36
514	Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design. <i>Journal of Drugs in Dermatology</i> , 2015, 14, 777-84.	0.8	20
515	Regulating off-label promotion of medications: has the pendulum swung too far?. <i>Skin Therapy Letter</i> , 2015, 20, 1-4.	0.3	0
516	Even well-controlled psoriasis patients have unmet treatment needs regardless of disease severity. <i>Dermatology Online Journal</i> , 2015, 21, .	0.5	1
517	A review of patient adherence to topical therapies for treatment of atopic dermatitis. <i>Cutis</i> , 2015, 96, 397-401.	0.3	23
518	Practical Strategies to Improve Patient Adherence to Treatment Regimens. <i>Southern Medical Journal</i> , 2015, 108, 325-31.	0.7	7
519	Commentary on "Safety and Efficacy of Combining Biologic with Nonbiologic Therapies for Moderate to Severe Psoriasis". <i>Psoriasis Forum</i> , 2014, 20a, 150-151.	0.1	0
520	Interleukin-17 in Atherosclerosis: Commentary. <i>Psoriasis Forum</i> , 2014, 20a, 59-59.	0.1	0
521	The National Ambulatory Medical Care Survey: A resource for understanding the outpatient dermatology treatment. <i>Journal of Dermatological Treatment</i> , 2014, 25, 453-458.	2.2	25
522	Are corticosteroids effective for prevention of scar formation after second-degree skin burn?. <i>Journal of Dermatological Treatment</i> , 2014, 25, 360-362.	2.2	13

#	ARTICLE	IF	CITATIONS
523	Measure of Atopic Dermatitis Disease Severity Using Actigraphy. Journal of Cutaneous Medicine and Surgery, 2014, 18, 49-55.	1.2	13
524	Are patients willing to participate in surveys?. Journal of Dermatological Treatment, 2014, 25, 365-366.	2.2	0
525	Systemic Corticosteroids Are Frequently Prescribed for Psoriasis. Journal of Cutaneous Medicine and Surgery, 2014, 18, 195-199.	1.2	19
526	Trends in Sunscreen Recommendation Among US Physicians. JAMA Dermatology, 2014, 150, 51.	4.1	37
527	Feasibility of actigraphy wristband monitoring of atopic dermatitis in children. Skin Research and Technology, 2014, 20, 510-514.	1.6	6
528	The association of skin conditions with housing conditions among North Carolina Latino migrant farm workers. International Journal of Dermatology, 2014, 53, 1091-1097.	1.0	15
529	Entrance and propagation pattern of high-frequency electrical currents in biological tissues as applied to fractional skin rejuvenation using penetrating electrodes. Skin Research and Technology, 2014, 20, 270-273.	1.6	15
530	Self-reported skin symptoms and skin-related quality of life among Latino immigrant poultry processing and other manual workers. American Journal of Industrial Medicine, 2014, 57, 605-614.	2.1	8
531	Improving medication adherence through technology: analyzing the managing meds video challenge. Skin Research and Technology, 2014, 20, 62-66.	1.6	12
532	What's new in the topical treatment of allergic skin diseases. Current Opinion in Allergy and Clinical Immunology, 2014, 14, 436-450.	2.3	8
533	A Conservative Method to Gutter Splint Ingrown Toenails. JAMA Dermatology, 2014, 150, 1359.	4.1	7
534	Analysis of a <i>New York Times</i> Article on the Public's Perception of Dermatologists. JAMA Dermatology, 2014, 150, 695.	4.1	2
535	Assessing Medication Adherence Using Indirect Self-report. JAMA Dermatology, 2014, 150, 813.	4.1	7
536	Comparing Demographic Characteristics and Adverse Event Rates at Two Dermatologic Surgery Practices. Journal of Cutaneous Medicine and Surgery, 2014, 18, 337-340.	1.2	6
537	Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology, 2014, 71, 327-349.	1.2	695
538	Improving patients' satisfaction with care. Clinics in Dermatology, 2014, 32, 444-447.	1.6	2
539	Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology, 2014, 71, 116-132.	1.2	970
540	Current and future evidence-based acne treatment: a review. Expert Opinion on Pharmacotherapy, 2014, 15, 173-192.	1.8	11

#	ARTICLE	IF	CITATIONS
541	Systemic Therapies for Psoriasis: An Evidence-Based Update. American Journal of Clinical Dermatology, 2014, 15, 165-180.	6.7	22
542	Medical Adherence to Acne Therapy: A Systematic Review. American Journal of Clinical Dermatology, 2014, 15, 87-94.	6.7	54
543	Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines. Pharmacoeconomics, 2014, 32, 395-409.	3.3	20
544	Safety and Tolerability of Tumor Necrosis Factor- α Inhibitors in Psoriasis: A Narrative Review. American Journal of Clinical Dermatology, 2014, 15, 37-43.	6.7	27
545	Electrosurgery. Journal of the American Academy of Dermatology, 2014, 70, 591.e1-591.e14.	1.2	88
546	Electrosurgery. Journal of the American Academy of Dermatology, 2014, 70, 607.e1-607.e12.	1.2	42
547	Research gaps in psoriasis: Opportunities for future studies. Journal of the American Academy of Dermatology, 2014, 70, 146-167.	1.2	101
548	Treatment failure of patients using topical acne treatments: an observational retrospective cohort study. Journal of Dermatological Treatment, 2014, 25, 193-195.	2.2	1
549	Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology, 2014, 70, 338-351.	1.2	889
550	Considerable variation among Scandinavian dermatologists in the dosing and monitoring of methotrexate for treating psoriasis. International Journal of Dermatology, 2014, 53, 385-389.	1.0	4
551	Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology, 2014, 71, 1218-1233.	1.2	256
552	Rosacea: New and Emerging Treatments. Drugs, 2014, 74, 1457-1465.	10.9	28
553	The Patient Protection and Affordable Care Act's rationing of health care: Implications for dermatology. Journal of the American Academy of Dermatology, 2014, 71, 998-999.	1.2	3
554	Use of St. John's Wort in Potentially Dangerous Combinations. Journal of Alternative and Complementary Medicine, 2014, 20, 578-579.	2.1	15
555	Topical antimicrobial acne treatment tolerability: A meaningful factor in treatment adherence?. Journal of the American Academy of Dermatology, 2014, 71, 581-582.e2.	1.2	8
556	Topical antibiotic monotherapy prescribing practices in acne vulgaris. Journal of Dermatological Treatment, 2014, 25, 97-99.	2.2	16
557	The economic burden of psoriasis: a systematic literature review. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 685-705.	1.4	64
558	Patterns of ambulatory care usage and leading treatments for rosacea. Journal of Dermatological Treatment, 2014, 25, 275-277.	2.2	4

#	ARTICLE	IF	CITATIONS
559	The psychological impact of rosacea and the influence of current management options. Journal of the American Academy of Dermatology, 2014, 71, 973-980.	1.2	115
560	Common Use of Prescription Off-Label Acne Therapy in Children Younger Than 12 Years Old. Pediatric Dermatology, 2014, 31, 551-555.	0.9	3
561	A painful eruption on the hands of a young man. Journal of the American Academy of Dermatology, 2014, 70, e25-e26.	1.2	0
562	Complementary and Alternative Medicine Use in Dermatology in the United States. Journal of Alternative and Complementary Medicine, 2014, 20, 392-398.	2.1	25
563	Are wash outs needed in clinical trials of topical agents?. Journal of Dermatological Treatment, 2014, 25, 1-1.	2.2	3
564	Phototherapy trends in dermatology. Journal of Dermatological Treatment, 2014, 25, 487-488.	2.2	3
565	Factors associated with topical retinoid prescriptions for acne. Journal of Dermatological Treatment, 2014, 25, 110-114.	2.2	6
566	Current Drug Therapies for Rosacea: A Chronic Vascular and Inflammatory Skin Disease. Journal of Managed Care Pharmacy, 2014, 20, 623-629.	2.2	12
567	Surge in US Outpatient Vitamin D Deficiency Diagnoses: National Ambulatory Medical Care Survey Analysis. Southern Medical Journal, 2014, 107, 214-217.	0.7	14
568	Comorbidity of Tinea Pedis and Onychomycosis and Evaluation of Risk Factors in Latino Immigrant Poultry Processing and Other Manual Laborers. Southern Medical Journal, 2014, 107, 374-379.	0.7	20
569	The cost of biologics for psoriasis is increasing. Drugs in Context, 2014, 3, 1-10.	2.2	48
570	Summary of Published Treatment Guidelines. , 2014, , 301-313.		0
571	Hyperkeratotic Eczema (Psoriasis) of the Palms. , 2014, , 139-147.		0
572	Commentary on "Gynecomastia: Etiologies, Clinical Presentations, Diagnosis, and Management" Southern Medical Journal, 2014, 107, 50-51.	0.7	0
573	Trends in the Use of Neurotoxins and Dermal Fillers by US Physicians. Journal of Clinical and Aesthetic Dermatology, 2014, 7, 14-9.	0.1	29
574	A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatology Online Journal, 2014, 20, 22608.	0.5	31
575	Common reasons why acne patients call the office. Dermatology Online Journal, 2014, 20, 22609.	0.5	1
576	Underuse of early follow-up visits: a missed opportunity to improve patients' adherence. Journal of Drugs in Dermatology, 2014, 13, 833-6.	0.8	17

#	ARTICLE	IF	CITATIONS
577	Social impact of the burden of psoriasis: effects on patients and practice. <i>Dermatology Online Journal</i> , 2014, 20, .	0.5	17
578	Erythema ab igne: evolving technology, evolving presentation. <i>Dermatology Online Journal</i> , 2014, 20, .	0.5	3
579	Home ultraviolet light therapy for psoriasis: why patients choose other options. <i>Dermatology Online Journal</i> , 2014, 21, .	0.5	1
580	Prescriptions for a toxic combination: use of methotrexate plus trimethoprim-sulfamethoxazole in the United States. <i>Southern Medical Journal</i> , 2014, 107, 292-3.	0.7	6
581	Treatment of Preadolescent Acne in the United States: An Analysis of Nationally Representative Data. <i>Pediatric Dermatology</i> , 2013, 30, 689-694.	0.9	22
582	Cost Effectiveness of Biologic Therapies for Plaque Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 315-326.	6.7	55
583	The Effect of Folate Supplementation on Methotrexate Efficacy and Toxicity in Psoriasis Patients and Folic Acid Use by Dermatologists in the USA. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 155-161.	6.7	25
584	A young boy with a perioral eruption. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, e159.	1.2	0
585	A disease of the present: Scurvy in "well-nourished" patients. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, e246-e247.	1.2	8
586	Treatment of Becker nevus with topical flutamide. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, e147-e148.	1.2	14
587	Foreword. <i>BioDrugs</i> , 2013, 27, 1-2.	4.6	26
588	Risk of Cardiovascular Disorders in Psoriasis Patients. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 1-7.	6.7	28
589	Medication Adherence, Healthcare Costs and Utilization Associated with Acne Drugs in Medicaid Enrollees with Acne Vulgaris. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 243-251.	6.7	37
590	Management of Keloids in the United States, 1990-2009: An Analysis of the National Ambulatory Medical Care Survey. <i>Dermatologic Surgery</i> , 2013, 39, 988-994.	0.8	28
591	Patterns of disease and treatment of cold sores. <i>Journal of Dermatological Treatment</i> , 2013, 24, 439-443.	2.2	2
592	Incidence, Risk Factors, and Preventative Management of Skin Cancers in Organ Transplant Recipients: A Review of Single- and Multicenter Retrospective Studies from 2006 to 2010. <i>Dermatologic Surgery</i> , 2013, 39, 345-364.	0.8	68
593	Patients' educational needs about topical treatments for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, e163-e168.	1.2	12
594	Combination Therapy in Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 9-25.	6.7	26

#	ARTICLE	IF	CITATIONS
595	Side effects of common acne treatments. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 39-51.	2.4	43
596	Use of electronic medical records differs by specialty and office settings. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2013, 20, e33-e38.	4.4	67
597	Maternal Adherence Factors in the Treatment of Pediatric Atopic Dermatitis. <i>JAMA Dermatology</i> , 2013, 149, 229.	4.1	16
598	Using a single product (calcipotriene/betamethasone topical suspension) vs multiple products to manage body and scalp psoriasis: comparisons in resource utilization and costs. <i>Journal of Medical Economics</i> , 2013, 16, 1405-1413.	2.1	3
599	Review: timing of office visits can be a powerful tool to improve adherence in the treatment of dermatologic conditions. <i>Journal of Dermatological Treatment</i> , 2013, 24, 82-88.	2.2	19
600	Decreasing frequency of office visits on fridays. <i>Journal of Dermatological Treatment</i> , 2013, 24, 405-407.	2.2	1
601	Skin Manifestations of Outpatient Adverse Drug Events in the United States: A National Analysis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013, 17, 269-275.	1.2	12
602	Nonmelanoma skin cancer treatment training varies across different medical specialists. <i>Journal of Dermatological Treatment</i> , 2013, 24, 215-220.	2.2	3
603	Patients are often terrified of treatments. <i>Journal of Dermatological Treatment</i> , 2013, 24, 81-81.	2.2	0
604	Comparing the lifetime risks of TNF-alpha inhibitor use to common benchmarks of risk. <i>Journal of Dermatological Treatment</i> , 2013, 24, 101-106.	2.2	11
605	Using Hawthorne Effects to Improve Adherence in Clinical Practice: Lessons From Clinical Trials. <i>JAMA Dermatology</i> , 2013, 149, 490.	4.1	24
606	Noncosmetic Skin-Related Procedures Performed in the United States: An Analysis of National Ambulatory Medical Care Survey Data from 1995 to 2010. <i>Dermatologic Surgery</i> , 2013, 39, 1912-1921.	0.8	12
607	Can light-field photography ease focusing on the scalp and oral cavity?. <i>Skin Research and Technology</i> , 2013, 19, 288-290.	1.6	5
608	Quantifying and Characterizing Adverse Events in Dermatologic Surgery. <i>Dermatologic Surgery</i> , 2013, 39, 872-878.	0.8	23
609	Focusing and depth of field in photography: application in dermatology practice. <i>Skin Research and Technology</i> , 2013, 19, n/a-n/a.	1.6	11
610	Cosmetic Procedures Performed in the United States: A 16-Year Analysis. <i>Dermatologic Surgery</i> , 2013, 39, 1351-1359.	0.8	17
611	Dermatologist-diagnosed skin diseases among immigrant Latino poultry processors and other manual workers in North Carolina, USA. <i>International Journal of Dermatology</i> , 2013, 52, 1342-1348.	1.0	14
612	Commentary: The Growing Skin Cancer Problem. <i>Dermatologic Surgery</i> , 2013, 39, 603-604.	0.8	0

#	ARTICLE	IF	CITATIONS
613	Tangential Shave Removal of Basal Cell Carcinoma. <i>Dermatologic Surgery</i> , 2013, 39, 1945-1946.	0.8	3
614	Prevalence of Psoriasis and Rosacea Comorbidities in the Outpatient Setting. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013, 17, 295-298.	1.2	1
615	Recruiting Underserved Mothers to Medical Research: Findings from North Carolina. <i>Journal of Health Care for the Poor and Underserved</i> , 2013, 24, 1801-1815.	0.8	3
616	Once-daily topical treatment for psoriasis: calcipotriene + betamethasone two-compound topical formulation. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2013, 7, 19.	1.8	3
617	Adherence to Adalimumab in Patients with Moderate to Severe Psoriasis. <i>Dermatology Online Journal</i> , 2013, 19, .	0.5	19
618	A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp. <i>Journal of Drugs in Dermatology</i> , 2013, 12, 300-6.	0.8	8
619	The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. <i>Journal of Drugs in Dermatology</i> , 2013, 12, 438-46.	0.8	15
620	Dermatologists' knowledge of and preferences regarding topical steroids. <i>Journal of Drugs in Dermatology</i> , 2013, 12, 786-9.	0.8	5
621	Adherence to adalimumab in patients with moderate to severe psoriasis. <i>Dermatology Online Journal</i> , 2013, 19, 18182.	0.5	19
622	Adherence to ustekinumab in psoriasis patients. <i>Journal of Drugs in Dermatology</i> , 2013, 12, 1090-2.	0.8	15
623	Disease burden and treatment adherence in psoriasis patients. <i>Cutis</i> , 2013, 92, 258-63.	0.3	26
624	Adherence to drug therapy. , 2013, , 34-39.e1.		0
625	How good are US dermatologists at discriminating skin cancers? A number-needed-to-treat analysis. <i>Journal of Dermatological Treatment</i> , 2012, 23, 65-69.	2.2	47
626	Isotretinoin and oral contraceptive use in female acne patients varies by physician specialty: analysis of data from the National Ambulatory Medical Care Survey. <i>Journal of Dermatological Treatment</i> , 2012, 23, 272-277.	2.2	7
627	Measuring patient satisfaction changes patient satisfaction. <i>Journal of Dermatological Treatment</i> , 2012, 23, 81-82.	2.2	7
628	Let's not presuppose that patients take their medications. <i>Journal of Dermatological Treatment</i> , 2012, 23, 317-317.	2.2	1
629	Reaching for better understanding across the globe. <i>Journal of Dermatological Treatment</i> , 2012, 23, 397-397.	2.2	0
630	Medication use and associated health care outcomes and costs for patients with psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2012, 23, 196-202.	2.2	8

#	ARTICLE	IF	CITATIONS
631	Trends in Pediatric Psoriasis Outpatient Health Care Delivery in the United States. Archives of Dermatology, 2012, 148, 66.	1.4	30
632	Efficacy of low-dose acitretin in the treatment of psoriasis. Journal of Dermatological Treatment, 2012, 23, 400-403.	2.2	6
633	Practice Gap in Patient Education. Archives of Dermatology, 2012, 148, 1255.	1.4	2
634	Practice Trends in the Treatment of Actinic Keratosis in the United States: 0.5% Fluorouracil and Combination Cryotherapy plus Fluorouracil are Underused despite Evidence of Benefit. Journal of Cutaneous Medicine and Surgery, 2012, 16, 107-114.	1.2	13
635	Pachydermodactyly From Repetitive Motion in Poultry Processing Workers. Archives of Dermatology, 2012, 148, 925-8.	1.4	29
636	Commentary: We Know How Much Mohs Is Done, but Is It Appropriate?. Dermatologic Surgery, 2012, 38, 1435-1436.	0.8	1
637	Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opinion on Drug Delivery, 2012, 9, 1263-1271.	5.0	105
638	Services Available and Their Effectiveness. Dermatologic Clinics, 2012, 30, 19-37.	1.7	2
639	Quality of Life Measures for Acne Patients. Dermatologic Clinics, 2012, 30, 293-300.	1.7	44
640	Sticker Charts: A Method for Improving Adherence to Treatment of Chronic Diseases in Children. Pediatric Dermatology, 2012, 29, 403-408.	0.9	17
641	Use of topical antibiotics as prophylaxis in clean dermatologic procedures. Journal of the American Academy of Dermatology, 2012, 66, 445-451.e3.	1.2	29
642	A review of targeted ultraviolet B phototherapy for psoriasis. Journal of the American Academy of Dermatology, 2012, 66, 664-672.	1.2	42
643	Who Will Take Care of Us? Exploring Differences in Respondents' Satisfaction with Primary Care vs Specialty Care Physicians. Health Outcomes Research in Medicine, 2012, 3, e3-e10.	0.6	3
644	Apremilast as a treatment for psoriasis. Expert Opinion on Pharmacotherapy, 2012, 13, 1761-1770.	1.8	11
645	Efficacy and Safety of Calcipotriene 0.005% Foam for the Treatment of Plaque-Type Psoriasis. American Journal of Clinical Dermatology, 2012, 13, 261-271.	6.7	10
646	Consensus Guidelines for the Management of Plaque Psoriasis. Archives of Dermatology, 2012, 148, 95.	1.4	148
647	Comparative Efficacy of Biologics in Psoriasis. American Journal of Clinical Dermatology, 2012, 13, 365-374.	6.7	52
648	The effect of reminder systems on patients' adherence to treatment. Patient Preference and Adherence, 2012, 6, 127.	1.8	118

#	ARTICLE	IF	CITATIONS
649	Calcipotriene foam, 0.005% in mild-to-moderate plaque psoriasis. <i>Expert Review of Dermatology</i> , 2012, 7, 17-26.	0.3	1
650	Patients' Satisfaction With Dermatology Residents. <i>Southern Medical Journal</i> , 2012, 105, 520-523.	0.7	6
651	Medications Used for Acne Vulgaris: Practice Trends and the Use of Topical Combination Products. <i>Combination Products in Therapy</i> , 2012, 2, 1.	1.1	0
652	Top dermatologic conditions in patients of color: an analysis of nationally representative data. <i>Journal of Drugs in Dermatology</i> , 2012, 11, 466-73.	0.8	65
653	JAK inhibitors in psoriasis: a promising new treatment modality. <i>Journal of Drugs in Dermatology</i> , 2012, 11, 913-8.	0.8	21
654	Digital videography assessment of patients' experiences using adapalene-benzoyl peroxide gel in the treatment of acne vulgaris. <i>Journal of Drugs in Dermatology</i> , 2012, 11, 919-25.	0.8	4
655	Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2011, 22, 138-143.	2.2	24
656	Patient Satisfaction with Outpatient Medical Care in the United States. <i>Health Outcomes Research in Medicine</i> , 2011, 2, e197-e202.	0.6	16
657	A review of phototherapy protocols for psoriasis treatment. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 936-949.	1.2	128
658	The efficacy of adapalene-benzoyl peroxide combination increases with number of acne lesions. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 1085-1091.	1.2	31
659	Is concomitant use of methotrexate and oral retinoids dangerous? A review of the data regarding this combination. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 791-793.	1.2	6
660	A randomized controlled pilot study of strategies to increase adherence in teenagers with acne vulgaris. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 793-795.	1.2	36
661	Nondermatologist physicians advertising the provision of skin care services. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, e111-e112.	1.2	0
662	Painful skin after sun exposure in a healthy child. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, e141.	1.2	0
663	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 137-174.	1.2	398
664	A consideration when interpreting outpatient data. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 1180-1181.	1.2	0
665	A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2041-2054.	1.8	56
666	Psoriasis Patient-Physician Interactions. <i>Psoriasis Forum</i> , 2011, 17a, 298-302.	0.1	0

#	ARTICLE	IF	CITATIONS
667	Patient satisfaction with obstetricians and gynecologists compared with other specialties: analysis of US self-reported survey data. <i>Patient Related Outcome Measures</i> , 2011, 2, 21.	1.2	11
668	Retinoid plus antimicrobial combination treatments for acne. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2011, 4, 79.	1.8	25
669	Recruiting underserved populations to dermatologic research: a systematic review. <i>International Journal of Dermatology</i> , 2011, 50, 385-395.	1.0	28
670	Monitoring psoriasis patients being treated with tumour necrosis factor inhibitors: use your judgment. <i>British Journal of Dermatology</i> , 2011, 165, 229-230.	1.5	2
671	Topical Antibiotic Trends from 1993 to 2007: Use of Topical Antibiotics for Non-Evidence-Based Indications. <i>Dermatologic Surgery</i> , 2011, 37, 1427-1433.	0.8	11
672	We Must Think Outside the Box to Understand Nonadherence. <i>Pediatric Dermatology</i> , 2011, 28, 353-353.	0.9	3
673	Changing Age of Acne Vulgaris Visits: Another Sign of Earlier Puberty?. <i>Pediatric Dermatology</i> , 2011, 28, 645-648.	0.9	30
674	An Internet-Based Survey and Improvement of Acne Treatment Outcomes. <i>Archives of Dermatology</i> , 2011, 147, 1223.	1.4	32
675	Importance of Providing Adequate Patient Information to Ensure Good Adherence and Outcomes. <i>Archives of Dermatology</i> , 2011, 147, 695.	1.4	2
676	Insight into psoriasis management: Commercial perspectives for the U.S. psoriasis market. <i>Journal of Dermatological Treatment</i> , 2011, 22, 18-26.	2.2	4
677	Trends in home phototherapy adoption in the US: Monetary disincentives are only the tip of the iceberg. <i>Journal of Dermatological Treatment</i> , 2011, 22, 27-30.	2.2	18
678	Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2011, 22, 65-74.	2.2	32
679	It isn't a perfect world. <i>Journal of Dermatological Treatment</i> , 2011, 22, 1-1.	2.2	0
680	Seasonal variations in dermatology manuscript submission. <i>Journal of Dermatological Treatment</i> , 2011, 22, 60-60.	2.2	1
681	The compliance pyramid. <i>Journal of Dermatological Treatment</i> , 2011, 22, 185-186.	2.2	3
682	Usage of complementary and alternative medicine for management of skin disease. <i>Journal of Dermatological Treatment</i> , 2011, 22, 306-308.	2.2	0
683	How patients experience and manage dryness and irritation from acne treatment. <i>Journal of Drugs in Dermatology</i> , 2011, 10, 605-8.	0.8	26
684	Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. <i>Cutis</i> , 2011, 87, 201-7.	0.3	86

#	ARTICLE	IF	CITATIONS
685	Dermpathâ€: a professional electronic mailing list for dermatopathology. Journal of Cutaneous Pathology, 2010, 37, 814-818.	1.3	0
686	PLACEBO RESPONSE?. Psychosomatic Medicine, 2010, 72, 505.	2.0	2
687	The Economic Impact of Non-Melanoma Skin Cancer: A Review. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 888-896.	4.9	99
688	Access to Unused Health Care. Southern Medical Journal, 2010, 103, 496.	0.7	0
689	Vitamin E and Allergic Contact Dermatitis. Dermatitis, 2010, 21, 148-153.	1.6	39
690	Detecting Adverse Events in Dermatologic Surgery. Dermatologic Surgery, 2010, 36, 8-14.	0.8	3
691	Commentary: Pitfalls of Frozen Section Biopsy. Dermatologic Surgery, 2010, 36, 1116-1117.	0.8	0
692	Acne vulgaris and depression: a retrospective examination. Journal of Cosmetic Dermatology, 2010, 9, 59-63.	1.6	88
693	Medication adherence among acne patients: a review. Journal of Cosmetic Dermatology, 2010, 9, 160-166.	1.6	30
694	Assessing adherence to dermatology treatments: a review of self-report and electronic measures. Skin Research and Technology, 2010, 16, 253-258.	1.6	39
695	Bilateral chondrodermatitis nodularis chronica helix in an elderly woman. International Journal of Dermatology, 2010, 49, 472-474.	1.0	4
696	Cause-specific mortality in patients with severe psoriasis. British Journal of Dermatology, 2010, 163, 449-449.	1.5	0
697	Health behaviour models: a framework for studying adherence in children with atopic dermatitis. Clinical and Experimental Dermatology, 2010, 35, 228-232.	1.3	10
698	IL-12/23 Inhibitors and Their Potential Benefits and Risks for Psoriasis Patients. Psoriasis Forum, 2010, 16a, 16-20.	0.1	2
699	A Review of the Efficacy and Safety of Combined Methotrexate and Ultraviolet B Phototherapy versus Ultraviolet B Phototherapy Alone in the Treatment of Psoriasis. Psoriasis Forum, 2010, 16a, 26-32.	0.1	0
700	Literature is lacking in discussion of non-adherence in dermatology. Journal of Dermatological Treatment, 2010, 21, 109-110.	2.2	5
701	Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006. Archives of Dermatology, 2010, 146, 283-7.	1.4	1,017
702	Conversations on psoriasis â€ what patients want and what physicians can provide: A qualitative look at patient and physician expectations. Journal of Dermatological Treatment, 2010, 21, 6-12.	2.2	56

#	ARTICLE	IF	CITATIONS
703	The prime directive for enhancing patients' medical experience. <i>Journal of Dermatological Treatment</i> , 2010, 21, 217-217.	2.2	1
704	Prescribing patterns for topical retinoids: Analyses of 15 years of data from the National Ambulatory Medical Care Survey. <i>Journal of Dermatological Treatment</i> , 2010, 21, 193-200.	2.2	9
705	Prior authorization for topical psoriasis treatments: Is it cost-beneficial for managed care?. <i>Journal of Dermatological Treatment</i> , 2010, 21, 178-184.	2.2	9
706	Physicians' perceptions of an eczema action plan for atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2010, 21, 28-33.	2.2	24
707	A Medicare cost comparison of minor cutaneous procedures by surgical setting. <i>Journal of Dermatological Treatment</i> , 2010, 21, 101-106.	2.2	3
708	Dermatological patient safety: Problems and solutions. <i>Journal of Dermatological Treatment</i> , 2010, 21, 86-92.	2.2	1
709	Simple means to enhance patients' perceptions of their physicians. <i>Journal of Dermatological Treatment</i> , 2010, 21, 61-61.	2.2	0
710	Cost-effectiveness of a hydroquinone/tretinoin/fluocinolone acetonide cream combination in treating melasma in the United States. <i>Journal of Dermatological Treatment</i> , 2010, 21, 276-281.	2.2	7
711	Perhaps programs are a better way to go. <i>Journal of Dermatological Treatment</i> , 2010, 21, 325-325.	2.2	1
712	A Randomized Controlled Pilot Study of the Effects of an Extra Office Visit on Adherence and Outcomes in Atopic Dermatitis. <i>Archives of Dermatology</i> , 2010, 146, 1428.	1.4	38
713	Psoriasis and its treatment with adalimumab. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 133-152.	3.1	5
714	The Role of Tetracyclines in Rosacea. <i>American Journal of Clinical Dermatology</i> , 2010, 11, 79-87.	6.7	32
715	Podcasting in dermatology education. <i>Journal of Dermatological Treatment</i> , 2010, 21, 73-79.	2.2	13
716	Estimating the time required for a complete skin examination. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 886-888.	1.2	8
717	Pyoderma gangrenosum: A review and update on new therapies. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 646-654.	1.2	197
718	Where did current academic dermatologists train?. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 522-523.	1.2	2
719	Factors affecting sleep quality in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 114-123.	1.2	97
720	Linear hyperpigmented lesions in an 8-year-old girl. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, e109.	1.2	0

#	ARTICLE	IF	CITATIONS
721	Drug samples in dermatology: Special considerations and recommendations for the future. Journal of the American Academy of Dermatology, 2010, 62, 1053-1061.	1.2	11
722	Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2010, 62, 114-135.	1.2	311
723	Hyperkeratotic plaques on the hands. Journal of the American Academy of Dermatology, 2010, 63, e95.	1.2	0
724	Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. Journal of the American Academy of Dermatology, 2010, 63, 457-465.	1.2	180
725	The clinical triage assistant: A new member of the dermatology health care team. Journal of the American Academy of Dermatology, 2010, 63, 1103-1105.	1.2	4
726	Psoralen plus ultraviolet A light phototherapy effectiveness. Journal of the American Academy of Dermatology, 2010, 63, 718.	1.2	1
727	Physician performance measures in dermatology. Journal of the American Academy of Dermatology, 2010, 63, e29-e35.	1.2	5
728	Understanding and Improving Treatment Adherence in Pediatric Patients. Seminars in Cutaneous Medicine and Surgery, 2010, 29, 137-140.	1.6	38
729	Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. Expert Opinion on Biological Therapy, 2010, 10, 1105-1112.	3.1	5
730	Vitamin D analogue-based therapies for psoriasis. Drugs of Today, 2010, 46, 351.	1.1	31
731	Trends in the treatment of acne vulgaris: are measures being taken to avoid antimicrobial resistance?. Journal of Drugs in Dermatology, 2010, 9, 519-24.	0.8	27
732	Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance. Journal of Drugs in Dermatology, 2010, 9, 324-9.	0.8	21
733	Acne vulgaris in the United States: a descriptive epidemiology. Cutis, 2010, 86, 94-9.	0.3	75
734	Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis, 2010, 86, 103-8.	0.3	57
735	Improvement in treatment adherence with a 3-day course of fluocinonide cream 0.1% for atopic dermatitis. Cutis, 2010, 86, 208-13.	0.3	12
736	Adherence, the Fourth Dimension in the Geometry of Dermatological Treatment. Archives of Dermatology, 2009, 145, 1319-21.	1.4	9
737	Severity levels in psoriasis: A separate "very severe" category not required. Journal of Dermatological Treatment, 2009, 20, 48-51.	2.2	0
738	Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis. Dermatology, 2009, 219, 209-218.	2.1	87

#	ARTICLE	IF	CITATIONS
739	Validation and Reliability of 2 Specialty Care Satisfaction Scales. American Journal of Medical Quality, 2009, 24, 12-18.	0.5	20
740	Adherence to a Topical Regimen of 5-Fluorouracil, 0.5%, Cream for the Treatment of Actinic Keratoses. Archives of Dermatology, 2009, 145, 203-5.	1.4	37
741	Adherence must always be considered: Is everolimus really ineffective as a treatment for atopic dermatitis?. Journal of Dermatological Treatment, 2009, 20, 317-318.	2.2	1
742	Equating Topical Treatment of Severe Psoriasis to Keeping Money in a Mattress. Journal of Dermatological Treatment, 2009, 20, 1-2.	2.2	5
743	Optimizing topical therapy for psoriasis. Expert Review of Dermatology, 2009, 4, 385-402.	0.3	2
744	Rheumatologists'™ recommendations on what to do in the dermatology office to evaluate and manage psoriasis patients'™ joint symptoms. Journal of Dermatological Treatment, 2009, 20, 350-353.	2.2	20
745	Radiofrequency heating for striae: Does it work?. Journal of Dermatological Treatment, 2009, 20, 318-318.	2.2	1
746	Tanning beds as an alternative for psoriasis when office-based phototherapy is not accessible. Journal of Dermatological Treatment, 2009, 20, 238-240.	2.2	5
747	Many new options for improving patients' care. Journal of Dermatological Treatment, 2009, 20, 185-185.	2.2	0
748	Methotrexate: Understanding the risk in psoriasis patients. Journal of Dermatological Treatment, 2009, 20, 311-313.	2.2	6
749	Monitoring for medication errors in outpatient settings. Journal of Dermatological Treatment, 2009, 20, 229-232.	2.2	7
750	The cost-effectiveness of rosacea treatments. Journal of Dermatological Treatment, 2009, 20, 72-75.	2.2	17
751	Tattooing practices in the migrant Latino farmworker population: risk for blood-borne disease. International Journal of Dermatology, 2009, 48, 1400-1402.	1.0	1
752	The prevalence of melasma and its association with quality of life in adult male Latino migrant workers. International Journal of Dermatology, 2009, 48, 22-26.	1.0	75
753	The prevalence and possible causes of contact dermatitis in farmworkers. International Journal of Dermatology, 2009, 48, 1166-1170.	1.0	19
754	Economic evaluation of systemic therapies for moderate to severe psoriasis. British Journal of Dermatology, 2009, 160, 1264-1272.	1.5	73
755	Using "number needed to treat"™ to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-1± inhibitors for patients with severe psoriasis. British Journal of Dermatology, 2009, 161, 605-616.	1.5	14
756	Tanning as an addictive behavior: a literature review. Photodermatology Photoimmunology and Photomedicine, 2009, 25, 12-19.	1.5	61

#	ARTICLE	IF	CITATIONS
757	Reappraising the phototoxicity of tretinoin: a report of four controlled clinical trials. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2009, 25, 146-152.	1.5	14
758	Commentary on "Indoor tanning injuries: an evaluation of FDA adverse event reporting data". <i>Photodermatology Photoimmunology and Photomedicine</i> , 2009, 25, 221-222.	1.5	1
759	Health Care Utilization Among Migrant Latino Farmworkers: The Case of Skin Disease. <i>Journal of Rural Health</i> , 2009, 25, 98-103.	2.9	31
760	Teledermatology Consultations Provide Specialty Care for Farmworkers in Rural Clinics. <i>Journal of Rural Health</i> , 2009, 25, 198-202.	2.9	22
761	Pharmacoeconomic Considerations in Treating Actinic Keratosis. <i>Pharmacoeconomics</i> , 2009, 27, 451-464.	3.3	62
762	Adherence to topical hydrocortisone 17-butyrate 0.1% in different vehicles in adults with atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 166-168.	1.2	18
763	Continued use of home narrowband ultraviolet B light phototherapy for psoriasis after completion of a clinical trial. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 877-879.	1.2	10
764	Increasing use of more potent treatments for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 478-481.	1.2	25
765	Microscopically differentiating dermatophytes from sock fibers. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 1024-1027.	1.2	8
766	An exploratory study of adherence to topical benzoyl peroxide in patients with acne vulgaris. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 879-880.	1.2	37
767	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 643-659.	1.2	419
768	Commentary: The relative ease of obtaining a dermatologic appointment in Boston. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 949-950.	1.2	2
769	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 451-485.	1.2	505
770	Pilot Study of the Effect of Ultraviolet Light on Pain and Mood in Fibromyalgia Syndrome. <i>Journal of Alternative and Complementary Medicine</i> , 2009, 15, 15-23.	2.1	13
771	Topical Clobetasol Propionate in the Treatment of Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2009, 10, 397-406.	6.7	45
772	Calcitriol ointment: A review of a topical vitamin D analog for psoriasis. <i>Journal of Dermatological Treatment</i> , 2009, 20, 208-212.	2.2	28
773	Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2555-2562.	1.8	85
774	Dermatologic Medication Adherence. <i>Dermatologic Clinics</i> , 2009, 27, 113-120.	1.7	13

#	ARTICLE	IF	CITATIONS
775	Ultraviolet Tanning Addiction. <i>Dermatologic Clinics</i> , 2009, 27, 109-112.	1.7	38
776	Effect of patient satisfaction on outcomes of care. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 393-395.	1.4	32
777	Management of Psoriasis. <i>Southern Medical Journal</i> , 2009, 102, 631-636.	0.7	0
778	Improving adherence to topical treatment. <i>Cutis</i> , 2009, 83, 215-7.	0.3	6
779	Are ointments better than other vehicles for corticosteroid treatment of psoriasis?. <i>Journal of Drugs in Dermatology</i> , 2009, 8, 570-2.	0.8	15
780	Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis. <i>Cutis</i> , 2009, 84, 25-32.	0.3	11
781	Development and validation of the Dermatomyositis Skin Severity Index. <i>British Journal of Dermatology</i> , 2008, 158, 345-350.	1.5	33
782	What Specialties Perform the Most Common Outpatient Cosmetic Procedures in the United States?. <i>Dermatologic Surgery</i> , 2008, 34, 1-8.	0.8	35
783	Self report of skin problems among farmworkers in North Carolina. <i>American Journal of Industrial Medicine</i> , 2008, 51, 204-212.	2.1	19
784	Green tobacco sickness and skin integrity among migrant latino farmworkers. <i>American Journal of Industrial Medicine</i> , 2008, 51, 195-203.	2.1	41
785	Differences in Acne Treatment Prescribing Patterns of Pediatricians and Dermatologists: An Analysis of Nationally Representative Data. <i>Pediatric Dermatology</i> , 2008, 25, 635-639.	0.9	22
786	Prevalence of pigmentary disorders and their impact on quality of life: a prospective cohort study. <i>Journal of Cosmetic Dermatology</i> , 2008, 7, 164-168.	1.6	68
787	Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2008, 159, 704-710.	1.5	76
788	The association of dermatologistâ€diagnosed and selfâ€reported skin diseases with skinâ€related quality of life in Latino migrant farmworkers. <i>International Journal of Dermatology</i> , 2008, 47, 236-241.	1.0	15
789	Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study. <i>Health and Quality of Life Outcomes</i> , 2008, 6, 75.	2.4	40
790	Systematic selection bias: A cause of dramatic errors in the inference of treatment effectiveness. <i>Journal of Dermatological Treatment</i> , 2008, 19, 68-71.	2.2	4
791	Open label trial of alefacept in palmoplantar pustular psoriasis. <i>Journal of Dermatological Treatment</i> , 2008, 19, 97-100.	2.2	23
792	Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 125-135.	1.2	76

#	ARTICLE	IF	CITATIONS
793	Reply: Interleukin-12, interleukin-23, and psoriasis: ABT-874 in clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 1083.	1.2	0
794	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 826-850.	1.2	1,128
795	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 851-864.	1.2	456
796	To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 970-977.	1.2	28
797	Written action plans: Potential for improving outcomes in children with atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 677-683.	1.2	59
798	Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 577-581.	1.2	32
799	Psoriasis: Improving adherence to topical therapy. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 1009-1016.	1.2	141
800	A Review of Adapalene in the Treatment of Acne Vulgaris. <i>Journal of Adolescent Health</i> , 2008, 43, 421-424.	2.5	36
801	The Relationship Between Physician-Friendliness and Caring, and Patient Satisfaction. <i>Patient</i> , 2008, 1, 91-96.	2.7	35
802	Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. <i>Current Medical Research and Opinion</i> , 2008, 24, 3493-3501.	1.9	13
803	Common Skin Disorders Seen in the Migrant Farmworker Health Care Clinic Setting. <i>Journal of Agromedicine</i> , 2008, 12, 71-79.	1.5	8
804	The pharmacoeconomics of acne treatment: Where are we heading?. <i>Journal of Dermatological Treatment</i> , 2008, 19, 27-37.	2.2	8
805	Targeted UV therapy in the treatment of psoriasis. <i>Journal of Dermatological Treatment</i> , 2008, 19, 141-145.	2.2	23
806	“Coral reef” psoriasis: A marker of resistance to topical treatment. <i>Journal of Dermatological Treatment</i> , 2008, 19, 257-258.	2.2	10
807	Skin-Related Quality of Life among Migrant Farmworkers. <i>Journal of Cutaneous Medicine and Surgery</i> , 2008, 12, 1-7.	1.2	12
808	The distress of psoriasis doesn't necessarily imply good treatment adherence: A lesson from the treatment of sexually transmitted disease. <i>Journal of Dermatological Treatment</i> , 2008, 19, 132-133.	2.2	2
809	Context and contrast. <i>Journal of Dermatological Treatment</i> , 2008, 19, 197-198.	2.2	3
810	Prescription refills and healthcare costs associated with topical metronidazole in Medicaid enrolled patients with rosacea. <i>Journal of Dermatological Treatment</i> , 2008, 19, 267-273.	2.2	9

#	ARTICLE	IF	CITATIONS
811	UV Light Abuse as a Substance-Related Disorder. Archives of Dermatology, 2008, 144, 1047-8.	1.4	11
812	Vision Problems, Eye Care History, and Ocular Protection Among Migrant Farmworkers. Archives of Environmental and Occupational Health, 2008, 63, 13-16.	1.4	28
813	Blistering Eruption in a Latino Migrant Farmworker. Journal of Agromedicine, 2008, 12, 81-85.	1.5	2
814	Home Narrowband UV-B Phototherapy in Combination With Low-Dose Acitretin in Patients With Moderate to Severe Psoriasis. Archives of Dermatology, 2008, 144, 1224-5.	1.4	13
815	Editorial: Mental Health and Psoriasis. Psoriasis Forum, 2008, 14a, 8-9.	0.1	0
816	Safety and Efficacy of 16 Weeks of 30 mg/Week Intramuscular Alefacept in the Treatment of Chronic Plaque Psoriasis. Psoriasis Forum, 2008, 14a, 10-13.	0.1	0
817	Self-Treatment with Bleach by a Latino Farmworker. Dermatitis, 2008, 19, 102-104.	1.6	8
818	Photographic assessment of tretinoin microsphere gel in moderate acne. Journal of Drugs in Dermatology, 2008, 7, s19-24.	0.8	0
819	Why don't patients get better? The three "nons". Journal of Dermatological Treatment, 2007, 18, 136-137.	2.2	1
820	What you should do when people don't get well. Journal of Dermatological Treatment, 2007, 18, 196-196.	2.2	1
821	A role for denial in poor adherence to psoriasis treatment. Journal of Dermatological Treatment, 2007, 18, 324-325.	2.2	7
822	Misunderstandings. Journal of Dermatological Treatment, 2007, 18, 4-4.	2.2	0
823	Measures used in specifying psoriasis lesion(s), global disease and quality of life: A systematic review. Journal of Dermatological Treatment, 2007, 18, 223-242.	2.2	38
824	Melasma and its impact on health-related quality of life in Hispanic women. Journal of Dermatological Treatment, 2007, 18, 5-9.	2.2	77
825	Cutaneous Larva Migrans in a Migrant Latino Farmworker. Journal of Agromedicine, 2007, 12, 45-48.	1.5	4
826	Quality of Dermatologic Care Delivered by Physician Assistants: An Analysis of Prescribing Behavior for the Combination Antifungal Agent Clotrimazole-Betamethasone. Archives of Dermatology, 2007, 143, 1591-2.	1.4	4
827	Alopecia in the United States: Outpatient utilization and common prescribing patterns. Journal of the American Academy of Dermatology, 2007, 57, S49-S51.	1.2	48
828	Stealth monitoring of adherence to topical medication: Adherence is very poor in children with atopic dermatitis. Journal of the American Academy of Dermatology, 2007, 56, 211-216.	1.2	237

#	ARTICLE	IF	CITATIONS
829	Cutaneous lupus erythematosus simulating squamous neoplasia: The clinicopathologic conundrum and histopathologic pitfalls. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 1013-1020.	1.2	21
830	An educational brochure helps improve patients' understanding of residents' role and level of training. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 165-167.	1.2	3
831	A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 31.e1-31.e15.	1.2	444
832	Adherence to topical therapy increases around the time of office visits. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 81-83.	1.2	173
833	Interleukin-12, interleukin-23, and psoriasis: Current prospects. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 1059-1068.	1.2	135
834	Eligibility creep: A cause for placebo group improvement in controlled trials of psoriasis treatments. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 972-976.	1.2	32
835	Poor Adherence to Treatments. <i>Archives of Dermatology</i> , 2007, 143, 912-5.	1.4	54
836	Correlates of patient satisfaction with physician visit: Differences between elderly and non-elderly survey respondents. <i>Health and Quality of Life Outcomes</i> , 2007, 5, 62.	2.4	42
837	A Randomized, Double-Blind Clinical Trial of a Probiotic Nutritional Intervention in the Treatment of Mild to Moderate Non-Scalp Psoriasis. <i>Psoriasis Forum</i> , 2007, 13a, 12-15.	0.1	3
838	Update on infliximab: an intravenous biologic therapy for psoriasis. <i>Expert Review of Dermatology</i> , 2007, 2, 707-713.	0.3	3
839	A Randomized, Double-Blind, Vehicle-Controlled, Right/Left Comparative Study of the Efficacy of Acitretin with and without the Co-Administration of 0.1% Tacrolimus Topical Ointment in the Treatment of Moderate to Severe Psoriasis. <i>Psoriasis Forum</i> , 2007, 13a, 16-20.	0.1	0
840	The importance of avoiding electrosurgical artifact at the margins of melanoma excisions. <i>Journal of Surgical Oncology</i> , 2007, 96, 637-638.	1.7	1
841	Does cost-effectiveness play a role in clinical trials?. <i>Dermatologic Therapy</i> , 2007, 20, 110-119.	1.7	7
842	Contact dermatitis in tobacco farmworkers. <i>Contact Dermatitis</i> , 2007, 57, 40-43.	1.4	17
843	US dermatopathology fellows career survey: 2004-2005. <i>Journal of Cutaneous Pathology</i> , 2007, 34, 487-489.	1.3	7
844	Analysis of NAMCS data for multiple sclerosis, 1998-2004. <i>BMC Medicine</i> , 2007, 5, 6.	5.5	10
845	The role of topical therapy for patients with extensive psoriasis. <i>Cutis</i> , 2007, 79, 18-31.	0.3	1
846	Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: add-on therapy in the COBRA trial. <i>Cutis</i> , 2007, 80, 20-8.	0.3	8

#	ARTICLE	IF	CITATIONS
847	Looking beyond the borders of our specialty: the 2006 Clarence S. Livingood MD Lecture. <i>Dermatology Online Journal</i> , 2007, 13, 20.	0.5	0
848	The Acne Quality of Life Index (Acne-QOLI). <i>American Journal of Clinical Dermatology</i> , 2006, 7, 185-192.	6.7	41
849	Cost-effectiveness of moderate-to-severe psoriasis treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 157-167.	1.8	36
850	Quality of life in patients with psoriasis. <i>Health and Quality of Life Outcomes</i> , 2006, 4, 35.	2.4	253
851	The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. <i>Journal of Dermatological Treatment</i> , 2006, 17, 29-37.	2.2	38
852	Tachyphylaxis to topical corticosteroids: the more you use them, the less they work?. <i>Clinics in Dermatology</i> , 2006, 24, 229-230.	1.6	45
853	Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 217-220.	1.2	98
854	Adherence with topical treatment is poor compared with adherence with oral agents: Implications for effective clinical use of topical agents. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, S235-S236.	1.2	61
855	Induction of withdrawal-like symptoms in a small randomized, controlled trial of opioid blockade in frequent tanners. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 709-711.	1.2	171
856	Dictation templates improve coding accuracy in an academic dermatology practice. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 539-540.	1.2	0
857	Plasma β -endorphin levels in frequent and infrequent tanners before and after ultraviolet and non-ultraviolet stimuli. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 919-920.	1.2	24
858	Adapting electronic adherence monitors to standard packages of topical medications. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 886-887.	1.2	12
859	Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 361-363.	1.2	2
860	Treatment Patterns and Cost of Nonmelanoma Skin Cancer Management. <i>Dermatologic Surgery</i> , 2006, 32, 1266-1271.	0.8	1
861	Social Sensitivity and ACNE: The Role of Personality in Negative Social Consequences and Quality of Life. <i>International Journal of Psychiatry in Medicine</i> , 2006, 36, 121-130.	1.8	29
862	Nonmelanoma Skin Cancer. <i>Dermatologic Surgery</i> , 2006, 32, 1473-1479.	0.8	64
863	Increase in Procedures Performed at Dermatology Office Visits from 1995 to 2001. <i>Dermatologic Surgery</i> , 2006, 31, 160-162.	0.8	13
864	Adverse Event Reporting: Lessons Learned from 4 Years of Florida Office Data. <i>Dermatologic Surgery</i> , 2006, 31, 1079-1093.	0.8	16

#	ARTICLE	IF	CITATIONS
865	Frequency and Cost of Actinic Keratosis Treatment. <i>Dermatologic Surgery</i> , 2006, 32, 1045-1049.	0.8	83
866	Treatment Patterns and Cost of Nonmelanoma Skin Cancer Management. <i>Dermatologic Surgery</i> , 2006, 32, 1266-1271.	0.8	64
867	Nonmelanoma Skin Cancer: Is the Incidence Really Increasing among Patients Younger Than 40? A Reexamination Using 25 years of U.S. Outpatient Data. <i>Dermatologic Surgery</i> , 2006, 32, 1473-1479.	0.8	16
868	The utility of a data-logging device for measuring adherence to home phototherapy. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2006, 22, 270-272.	1.5	7
869	Correlates of health-related quality of life in women with severe facial blemishes. <i>International Journal of Dermatology</i> , 2006, 45, 111-115.	1.0	75
870	Psoriasis treatment in the United States at the end of the 20th century. <i>International Journal of Dermatology</i> , 2006, 45, 370-374.	1.0	35
871	Latino farmworker perceptions of the risk factors for occupational skin disease. <i>American Journal of Industrial Medicine</i> , 2006, 49, 434-442.	2.1	25
872	Trends in on and off-label calcipotriene use. <i>Journal of Dermatological Treatment</i> , 2006, 17, 308-313.	2.2	2
873	Intermittent dosing of biologics for psoriasis. <i>Journal of Dermatological Treatment</i> , 2006, 17, 5-5.	2.2	1
874	The negative impact of psoriasis on the workplace. <i>Journal of Dermatological Treatment</i> , 2006, 17, 24-28.	2.2	84
875	Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2006, 17, 294-301.	2.2	65
876	Resident Education: Effect of the Sixth National Psoriasis Foundation Chief Residents' Meeting. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006, 10, 16-20.	1.2	6
877	How much of a topical agent should be prescribed for children of different sizes?. <i>Journal of Dermatological Treatment</i> , 2006, 17, 224-228.	2.2	16
878	Predictors of treatment choices and associated outcomes in actinic keratoses: Results from a national physician survey study. <i>Journal of Dermatological Treatment</i> , 2006, 17, 162-166.	2.2	24
879	Critical factors determining the potency of topical corticosteroids. <i>Journal of Dermatological Treatment</i> , 2006, 17, 133-135.	2.2	17
880	Prescribing on the basis of subjective disease severity. <i>Journal of Dermatological Treatment</i> , 2006, 17, 261-261.	2.2	2
881	Low-Dose Acitretin Is Associated With Fewer Adverse Events Than High-Dose Acitretin in the Treatment of Psoriasis. <i>Archives of Dermatology</i> , 2006, 142, 1000-4.	1.4	45
882	Death from psoriasis: Representative US data. <i>Journal of Dermatological Treatment</i> , 2006, 17, 302-303.	2.2	8

#	ARTICLE	IF	CITATIONS
883	Adherence in dermatology: A review of the last 20 years. <i>Journal of Dermatological Treatment</i> , 2006, 17, 136-142.	2.2	67
884	Novel combination regimens: Biologics and acitretin for the treatment of psoriasis – a case series. <i>Journal of Dermatological Treatment</i> , 2006, 17, 86-89.	2.2	40
885	Treating Skin Disease. <i>Journal of Agromedicine</i> , 2006, 11, 27-35.	1.5	39
886	New treatments for psoriasis: Which biologic is best?. <i>Journal of Dermatological Treatment</i> , 2006, 17, 96-107.	2.2	23
887	Do utilization management controls for phototherapy increase the prescription of biologics?. <i>Journal of Dermatological Treatment</i> , 2006, 17, 359-361.	2.2	17
888	Adverse events from systemic therapies for psoriasis are common in clinical practice. <i>Journal of Dermatological Treatment</i> , 2006, 17, 288-293.	2.2	24
889	What Is the Best Approach to Reducing Birth Defects Associated with Isotretinoin?. <i>PLoS Medicine</i> , 2006, 3, e483.	8.4	50
890	Members of the National Psoriasis Foundation. <i>Archives of Dermatology</i> , 2005, 141, 19-26.	1.4	61
891	The Touch of a Helping Hand. <i>Journal of Dermatological Treatment</i> , 2005, 16, 9-9.	2.2	0
892	Clinical Diagnosis of Actinic Keratosis Identifies an Elderly Population at High Risk of Developing Skin Cancer. <i>Dermatologic Surgery</i> , 2005, 31, 43-47.	0.8	31
893	Increase in Procedures Performed at Dermatology Office Visits from 1995 to 2001. <i>Dermatologic Surgery</i> , 2005, 31, 160-162.	0.8	16
894	Tanning and Skin Cancer. <i>Pediatric Dermatology</i> , 2005, 22, 501-512.	0.9	38
895	The Burden of Atopic Dermatitis: Impact on the Patient, Family, and Society. <i>Pediatric Dermatology</i> , 2005, 22, 192-199.	0.9	408
896	The Self-Administered Psoriasis Area and Severity Index provides an objective measure of psoriasis severity. <i>British Journal of Dermatology</i> , 2005, 152, 382-383.	1.5	29
897	Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. <i>British Journal of Dermatology</i> , 2005, 152, 954-960.	1.5	124
898	Patients with solar keratosis, particularly of the trunk or lower extremities, are at high risk for skin cancer development. <i>Clinical and Experimental Dermatology</i> , 2005, 30, 717-718.	1.3	6
899	Indoor tanning relieves pain. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2005, 21, 278-278.	1.5	8
900	We need more cross-disciplinary communication. <i>Journal of Dermatological Treatment</i> , 2005, 16, 257-257.	2.2	0

#	ARTICLE	IF	CITATIONS
901	A reappraisal of the concept of suppressive versus remittive psoriasis treatments. Journal of Dermatological Treatment, 2005, 16, 171-174.	2.2	0
902	Where has Goeckerman treatment gone?. Journal of Dermatological Treatment, 2005, 16, 73-74.	2.2	6
903	Does the teratogenicity of isotretinoin outweigh its benefits?. Journal of Dermatological Treatment, 2005, 16, 190-192.	2.2	6
904	Infliximab for inpatient psoriasis management "is there a role?. Journal of Dermatological Treatment, 2005, 16, 314-318.	2.2	1
905	The comorbid state of psoriasis patients in a university dermatology practice. Journal of Dermatological Treatment, 2005, 16, 319-323.	2.2	104
906	The rise of the generic drug market and its implications for dermatology. Journal of Dermatological Treatment, 2005, 16, 295-298.	2.2	4
907	The role of commercial tanning beds and ultraviolet A light in the treatment of psoriasis. Journal of Dermatological Treatment, 2005, 16, 324-326.	2.2	6
908	Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. Journal of Dermatological Treatment, 2005, 16, 158-164.	2.2	21
909	Incidence Rates, Costs, Severity, and Work-Related Factors of Occupational Dermatitis. Archives of Dermatology, 2005, 141, 713-8.	1.4	45
910	Trends in prescription of acne medication in the US: Shift from antibiotic to non-antibiotic treatment. Journal of Dermatological Treatment, 2005, 16, 224-228.	2.2	22
911	Systemic treatment for moderate to severe psoriasis: Estimates of failure rates and direct medical costs in a north-eastern US managed care plan. Journal of Dermatological Treatment, 2005, 16, 37-42.	2.2	27
912	Psoriasis assessment tools in clinical trials. Annals of the Rheumatic Diseases, 2005, 64, ii65-ii68.	0.9	359
913	The Skinny on Psoriasis and Obesity. Archives of Dermatology, 2005, 141, 1601-2.	1.4	35
914	Proven Efficacy of Tacrolimus for Facial and Intertriginous Psoriasis. Archives of Dermatology, 2005, 141, 1154.	1.4	27
915	Topical Tacrolimus Ointment Combined With 6% Salicylic Acid Gel for Plaque Psoriasis Treatment. Archives of Dermatology, 2005, 141, 43-6.	1.4	52
916	Definitions of Measures of Effect Duration for Psoriasis Treatments. Archives of Dermatology, 2005, 141, 82-4.	1.4	58
917	Healthcare Utilization for Acute and Chronic Diseases of Young, School-age Children in the Rural and Non-rural Setting. Clinical Pediatrics, 2005, 44, 491-498.	0.8	19
918	Dermatological Illnesses of Immigrant Poultry-Processing Workers in North Carolina. Archives of Environmental and Occupational Health, 2005, 60, 165-169.	1.4	18

#	ARTICLE	IF	CITATIONS
919	The prevalence of psoriasis in African Americans: Results from a population-based study. Journal of the American Academy of Dermatology, 2005, 52, 23-26.	1.2	250
920	Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States. Journal of the American Academy of Dermatology, 2005, 52, 27-31.	1.2	15
921	Systemic therapy does not usually clear psoriasis, but treatment success does not require clearing. Journal of the American Academy of Dermatology, 2005, 52, 140-141.	1.2	3
922	Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. Journal of the American Academy of Dermatology, 2005, 52, 425-433.	1.2	216
923	Traditional systemic treatments have not fully met the needs of psoriasis patients: Results from a national survey. Journal of the American Academy of Dermatology, 2005, 52, 434-444.	1.2	100
924	Health insurance benefit limits: General concepts and the potential impact on dermatologic treatment. Journal of the American Academy of Dermatology, 2005, 53, 140-142.	1.2	1
925	Side effects of naltrexone observed in frequent tanners: Could frequent tanners have ultraviolet-induced high opioid levels?. Journal of the American Academy of Dermatology, 2005, 52, 916.	1.2	21
926	Epidemiology of psoriatic arthritis in the population of the United States. Journal of the American Academy of Dermatology, 2005, 53, 573.e1-573.e13.	1.2	499
927	The cutaneous surgery experience of multiple specialties in the Medicare population. Journal of the American Academy of Dermatology, 2005, 52, 1045-1048.	1.2	26
928	Decision points for the initiation of systemic treatment for psoriasis. Journal of the American Academy of Dermatology, 2005, 53, 101-107.	1.2	72
929	Involving the patient: Impact of inflammatory skin disease and patient-focused care. Journal of the American Academy of Dermatology, 2005, 53, S78-S85.	1.2	48
930	The extent of dermatopathology education: A comparison of pathology and dermatology. Journal of the American Academy of Dermatology, 2005, 53, 694-697.	1.2	23
931	Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial. Journal of the American Academy of Dermatology, 2005, 53, 887-889.	1.2	77
932	Relative efficacy and interchangeability of various clobetasol propionate vehicles in the management of steroid-responsive dermatoses. Current Therapeutic Research, 2005, 66, 154-171.	1.2	12
933	The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Seminars in Cutaneous Medicine and Surgery, 2005, 24, 52-57.	1.6	36
934	Corrective cosmetics are effective for women with facial pigmentary disorders. Cutis, 2005, 75, 181-7.	0.3	15
935	The Frequent Use of Oral Retinoids in Combination with other Treatments for Psoriasis: A Retrospective Analysis. Journal of Cutaneous Medicine and Surgery, 2004, 8, 411-414.	1.2	7
936	The Safety of Office-Based Surgery. Archives of Dermatology, 2004, 140, 1379-82.	1.4	55

#	ARTICLE	IF	CITATIONS
937	A maintenance protocol for psoriasis plaques cleared by the 308nm excimer laser. <i>Journal of Dermatological Treatment</i> , 2004, 15, 94-97.	2.2	20
938	Management and costs of severe psoriasis: the role of new biologics. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004, 4, 573-579.	1.4	3
939	Editorial. <i>Journal of Dermatological Treatment</i> , 2004, 15, 71-71.	2.2	0
940	A topical azithromycin preparation for the treatment of acne vulgaris and rosacea. <i>Journal of Dermatological Treatment</i> , 2004, 15, 295-302.	2.2	16
941	Class I topical corticosteroid use by psoriasis patients in an academic practice. <i>Journal of Dermatological Treatment</i> , 2004, 15, 235-238.	2.2	12
942	Giving patients "perceived control" over psoriasis: advice for optimizing the physician-patient relationship. <i>Journal of Dermatological Treatment</i> , 2004, 15, 182-184.	2.2	15
943	Correspondence. <i>Journal of Dermatological Treatment</i> , 2004, 15, 252-252.	2.2	8
944	Prescribing practices for seborrheic dermatitis vary with the physician's specialty: implications for clinical practice. <i>Journal of Dermatological Treatment</i> , 2004, 15, 208-213.	2.2	12
945	Racial differences in the treatment of pigmentation disorders in outpatient settings: analysis of US national practice data. <i>Journal of Dermatological Treatment</i> , 2004, 15, 227-230.	2.2	11
946	Treatment of pityriasis versicolor in the United States. <i>Journal of Dermatological Treatment</i> , 2004, 15, 189-192.	2.2	21
947	Statistical Significance and Clinical Relevance. <i>Archives of Dermatology</i> , 2004, 140, 1520-3.	1.4	63
948	The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life?. <i>Dermatologic Therapy</i> , 2004, 17, 376-382.	1.7	23
949	Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2004, 150, 317-326.	1.5	99
950	Anger and acne: implications for quality of life, patient satisfaction and clinical care. <i>British Journal of Dermatology</i> , 2004, 151, 183-189.	1.5	102
951	Better medication adherence results in greater improvement in severity of psoriasis. <i>British Journal of Dermatology</i> , 2004, 151, 895-897.	1.5	127
952	Pruritus in adult dermatomyositis. <i>Clinical and Experimental Dermatology</i> , 2004, 29, 273-276.	1.3	67
953	Patients Spend More Time With the Physician for Excision of a Malignant Skin Lesion Than for Excision of a Benign Skin Lesion. <i>Dermatologic Surgery</i> , 2004, 30, 351-354.	0.8	1
954	Why Are There Differences in the Perceived Safety of Office-Based Surgery?. <i>Dermatologic Surgery</i> , 2004, 30, 1377-1379.	0.8	33

#	ARTICLE	IF	CITATIONS
955	Cyclosporin in psoriasis: how?. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 250-253.	2.4	1
956	Patient Demographics and Utilization of Health Care Services for Molluscum Contagiosum. Pediatric Dermatology, 2004, 21, 628-632.	0.9	28
957	Seasonal variation of dermatologic disease in the USA: a study of office visits from 1990 to 1998. International Journal of Dermatology, 2004, 43, 6-11.	1.0	93
958	The Frequent Use of Oral Retinoids in Combination with Other Treatments for Psoriasis: A Retrospective Analysis. Journal of Cutaneous Medicine and Surgery, 2004, 8, 411-414.	1.2	9
959	Analysis of factors associated with prescription of a potentially inappropriate combination dermatological medication among US outpatient physicians. Pharmacoepidemiology and Drug Safety, 2004, 13, 133-138.	1.9	10
960	Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction. Journal of Investigative Dermatology Symposium Proceedings, 2004, 9, 136-139.	0.8	618
961	A quantitative definition of severe psoriasis for use in clinical trials. Journal of Dermatological Treatment, 2004, 15, 27-29.	2.2	81
962	Combination therapy to treat moderate to severe psoriasis. Journal of the American Academy of Dermatology, 2004, 50, 416-430.	1.2	178
963	A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. Journal of the American Academy of Dermatology, 2004, 50, 859-866.	1.2	249
964	Prevalence and relevance of contact dermatitis allergens: A meta-analysis of 15 years of published T.R.U.E. test data. Journal of the American Academy of Dermatology, 2004, 51, 349-353.	1.2	106
965	Measurement of health-related quality of life (HRQOL) associated with skin disease. Journal of the American Academy of Dermatology, 2004, 51, 3-4.	1.2	10
966	Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: Commonly used methods of measuring adherence to topical therapy overestimate actual use. Journal of the American Academy of Dermatology, 2004, 51, 212-216.	1.2	181
967	Ultraviolet exposure is a reinforcing stimulus in frequent indoor tanners. Journal of the American Academy of Dermatology, 2004, 51, 45-51.	1.2	171
968	American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. Journal of the American Academy of Dermatology, 2004, 50, 900-906.	1.2	93
969	Determinants of quality of life in patients with psoriasis: A study from the US population. Journal of the American Academy of Dermatology, 2004, 51, 704-708.	1.2	305
970	Tacrolimus ointment is effective for facial and intertriginous psoriasis. Journal of the American Academy of Dermatology, 2004, 51, 723-730.	1.2	166
971	Surgery for basal-cell carcinoma of the face. Lancet, The, 2004, 364, 1732-1733.	13.7	13
972	Diagnosis and treatment of acne. American Family Physician, 2004, 69, 2123-30.	0.1	48

#	ARTICLE	IF	CITATIONS
973	A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. <i>Dermatology Online Journal</i> , 2004, 10, 7.	0.5	27
974	Terbinafine is More Effective Than Itraconazole in Treating Toenail Onychomycosis: Results from a Meta-analysis of Randomized Controlled Trials. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 306-311.	1.2	18
975	The Importance of Skin Disease as Assessed by "Willingness-To-Pay". <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 369-371.	1.2	11
976	Coding Multiple Diagnoses for Patient Visits at Which Procedures Were Performed: No Evidence for Abuse by Physicians. <i>Dermatologic Surgery</i> , 2003, 29, 150-154.	0.8	4
977	Nonmelanoma Skin Cancer: An Episode of Care Management Approach. <i>Dermatologic Surgery</i> , 2003, 29, 700-711.	0.8	35
978	Frequency of Seborrheic Keratosis Biopsies in the United States: A Benchmark of Skin Lesion Care Quality and Cost Effectiveness. <i>Dermatologic Surgery</i> , 2003, 29, 796-801.	0.8	18
979	No Smoking Gun: Findings From a National Survey of Office-Based Cosmetic Surgery Adverse Event Reporting. <i>Dermatologic Surgery</i> , 2003, 29, 1093-1099.	0.8	18
980	The Family Impact of Atopic Dermatitis in Children: The Role of the Parent Caregiver. <i>Pediatric Dermatology</i> , 2003, 20, 5-10.	0.9	44
981	Treatment of Psoriasis in Children: Is There a Role for Antibiotic Therapy and Tonsillectomy?. <i>Pediatric Dermatology</i> , 2003, 20, 11-15.	0.9	53
982	Health Care Utilization in Patients With Migraine: Demographics and Patterns of Care in the Ambulatory Setting. <i>Headache</i> , 2003, 43, 330-335.	3.9	72
983	Development and validation of a health-related quality of life instrument for women with melasma. <i>British Journal of Dermatology</i> , 2003, 149, 572-577.	1.5	202
984	Surgical Treatment of Nonmelanoma Skin Cancer in the Medicare Population. <i>Dermatologic Surgery</i> , 2003, 29, 1167-1169.	0.8	36
985	Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 39-43.	1.2	28
986	The design of clinical trials in psoriasis: lessons for clinical practice. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 62-65.	1.2	15
987	The economic burden of skin disease in the United States. <i>Journal of the American Academy of Dermatology</i> , 2003, 48, 592-599.	1.2	35
988	Skin cancer is among the most costly of all cancers to treat for the Medicare population. <i>Journal of the American Academy of Dermatology</i> , 2003, 48, 425-429.	1.2	438
989	The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 79-82.	1.2	21
990	Electronic monitoring of medication adherence in skin disease: Results of a pilot study. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 651-654.	1.2	72

#	ARTICLE	IF	CITATIONS
991	Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 271-275.	1.2	143
992	Are there racial and sex differences in the use of oral isotretinoin for acne management in the United States?. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 662-666.	1.2	35
993	Bioavailability of Clobetasol Propionate in Different Vehicles. <i>Skin Pharmacology and Physiology</i> , 2003, 16, 212-216.	2.5	19
994	Patients??? Vehicle Preference for Corticosteroid Treatments of Scalp Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2003, 4, 221-224.	6.7	67
995	Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1525-1533.	1.8	58
996	Disease severity and associated family impact in childhood atopic dermatitis. <i>Archives of Disease in Childhood</i> , 2003, 88, 423-427.	1.9	52
997	Editorial. <i>Journal of Dermatological Treatment</i> , 2003, 14, 198-199.	2.2	1
998	Physicians underutilize topical retinoids in the management of acne vulgaris: analysis of U.S. National Practice Data. <i>Journal of Dermatological Treatment</i> , 2003, 14, 172-176.	2.2	16
999	Case studies in severe psoriasis: A clinical strategy. <i>Journal of Dermatological Treatment</i> , 2003, 14, 26-46.	2.2	24
1000	Surgical Treatment of Nonmelanoma Skin Cancer in the Medicare Population. <i>Dermatologic Surgery</i> , 2003, 29, 1167-1169.	0.8	13
1001	Nonmelanoma Skin Cancer. <i>Dermatologic Surgery</i> , 2003, 29, 700-711.	0.8	18
1002	Efficacy, Safety, and Cost of Office-Based Surgery. <i>Dermatologic Surgery</i> , 2003, 29, 1-6.	0.8	55
1003	The Importance of Skin Disease as Assessed by "Willingness-To-Pay". <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 369-371.	1.2	16
1004	Bioterrorism Preparedness in the Dermatology Community. <i>Archives of Dermatology</i> , 2003, 139, 1657-8.	1.4	6
1005	Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1525-1533.	1.8	1
1006	Psoriasis and Pregnancy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 561-570.	1.2	56
1007	Phototherapy utilization for psoriasis is declining in the United States. <i>Journal of the American Academy of Dermatology</i> , 2002, 46, 557-559.	1.2	57
1008	Efficacy of the 308-nm excimer laser for treatment of psoriasis: Results of a multicenter study. <i>Journal of the American Academy of Dermatology</i> , 2002, 46, 900-906.	1.2	178

#	ARTICLE	IF	CITATIONS
1009	Off-label prescribing in the treatment of dermatologic disease. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 217-223.	1.2	54
1010	Definitions of Measures of Effect Duration for Psoriasis Treatments. <i>Psoriasis Forum</i> , 2002, 8a, 1-5.	0.1	14
1011	Effects of systematic asymmetric discounting on physician-patient interactions: a theoretical framework to explain poor compliance with lifestyle counseling. <i>BMC Medical Informatics and Decision Making</i> , 2002, 2, 8.	3.0	12
1012	Follow-up survey of 308-nm laser treatment of psoriasis. <i>Lasers in Surgery and Medicine</i> , 2002, 31, 202-206.	2.1	21
1013	Use of Transcutaneous Nerve Stimulation Wristband to Treat Methotrexate-Induced Nausea. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 551-553.	1.2	0
1014	Psoriasis and Pregnancy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 561-570.	1.2	94
1015	Visual discrimination testing of ultraviolet transmitting and ultraviolet blocking acrylic thermoplastics. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2002, 18, 228-231.	1.5	4
1016	The Safety of Liposuction: Results of a National Survey. <i>Dermatologic Surgery</i> , 2002, 28, 971-978.	0.8	137
1017	Use of the Self-Administered Eczema Area and Severity Index by parent caregivers: results of a validation study. <i>British Journal of Dermatology</i> , 2002, 147, 1192-1198.	1.5	86
1018	A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. <i>International Journal of Dermatology</i> , 2002, 41, 269-274.	1.0	50
1019	Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. <i>Cutis</i> , 2002, 70, 327-32.	0.3	71
1020	The specialty of the treating physician affects the likelihood of tumor-free resection margins for basal cell carcinoma: Results from a multi-institutional retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 224-230.	1.2	67
1021	1999 Special Olympics World Summer Games: Dermatologic health screening results. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 700-703.	1.2	4
1022	Patients seen in a dermatology clinic have unmet preventive health care needs. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 706-709.	1.2	6
1023	Implications of a utility model for ultraviolet exposure behavior. <i>Journal of the American Academy of Dermatology</i> , 2001, 45, 718-722.	1.2	13
1024	Demographics of aging and skin disease. <i>Clinics in Geriatric Medicine</i> , 2001, 17, 631-641.	2.6	28
1025	Betamethasone Valerate in Foam Vehicle is Effective with Both Daily and Twice a Day Dosing: A Single-Blind, Open-Label Study in the Treatment of Scalp Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 386-389.	1.2	19
1026	Dermatologists and Allergists Have Far More Experience and Use More Complex Treatment Regimens in the Treatment of Atopic Dermatitis Than other Physicians. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 211-216.	1.2	4

#	ARTICLE	IF	CITATIONS
1027	Dermatologists and Allergists Have Far More Experience and Use More Complex Treatment Regimens in the Treatment of Atopic Dermatitis Than Other Physicians. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 211-216.	1.2	7
1028	Betamethasone Valerate in Foam Vehicle Is Effective with Both Daily and Twice a Day Dosing: A Single-Blind, Open-Label Study in the Treatment of Scalp Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 386-389.	1.2	24
1029	Lifestyle high-risk behaviors and demographics may predict the level of participation in sun-protection behaviors and skin cancer primary prevention in the united states. <i>Cancer</i> , 2001, 92, 1315-1324.	4.1	107
1030	Cost of Nonmelanoma Skin Cancer Treatment in the United States. <i>Dermatologic Surgery</i> , 2001, 27, 1035-1038.	0.8	168
1031	Women commonly seek care for rosacea: dermatologists frequently provide the care. <i>Cutis</i> , 2001, 68, 156-60.	0.3	15
1032	Transmittance Properties of Flurandrenolide Tape for Psoriasis: Helpful Adjunct to Phototherapy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2000, 4, 196-198.	1.2	2
1033	Per-Gram Cost of Medication is by Itself a Poor Indicator for Comparing Costs of Different Psoriasis Treatments: A Retrospective Cohort Study of the Cost of Psoriasis Treatment with Topical Corticosteroids versus Topical Calcipotriene. <i>Journal of Cutaneous Medicine and Surgery</i> , 2000, 4, 121-125.	1.2	5
1034	Oral Griseofulvin Remains the Treatment of Choice for Tinea Capitis in Children. <i>Pediatric Dermatology</i> , 2000, 17, 304-309.	0.9	71
1035	New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. <i>International Journal of Dermatology</i> , 2000, 39, 41-44.	1.0	44
1036	Sex-specific differences in the treatment of severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2000, 42, 620-623.	1.2	28
1037	Clearance is not a realistic expectation of psoriasis treatment. <i>Journal of the American Academy of Dermatology</i> , 2000, 42, 796-802.	1.2	101
1038	Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles. <i>Journal of the American Academy of Dermatology</i> , 2000, 42, 1017-1020.	1.2	27
1039	Two considerations for patients with psoriasis and their clinicians:. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 281-285.	1.2	218
1040	Allergists and dermatologists have far more expertise in caring for patients with urticaria than other specialists. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 1084-1091.	1.2	22
1041	THE MAGNITUDE OF SKIN DISEASE IN THE UNITED STATES. <i>Dermatologic Clinics</i> , 2000, 18, xv-xxi.	1.7	30
1042	Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles. <i>Journal of the American Academy of Dermatology</i> , 2000, 42, 1017-20.	1.2	6
1043	Regarding Malpractice Claims. <i>Dermatologic Surgery</i> , 1999, 25, 737-738.	0.8	0
1044	Clinical Trial Size and Efficacy. <i>Dermatologic Surgery</i> , 1999, 25, 670-671.	0.8	0

#	ARTICLE	IF	CITATIONS
1045	Tobacco smoking contributes little to facial wrinkling. Journal of the European Academy of Dermatology and Venereology, 1999, 12, 133-139.	2.4	42
1046	Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology, 1999, 41, 401-407.	1.2	1,325
1047	Destructive procedures are the standard of care for treatment of actinic keratoses. Journal of the American Academy of Dermatology, 1999, 40, 43-47.	1.2	69
1048	Prescription of high-potency corticosteroid agents and clotrimazole-betamethasone dipropionate by pediatricians. Clinical Therapeutics, 1999, 21, 1725-1731.	2.5	34
1049	The SAPASI Is Valid and Responsive to Psoriasis Disease Severity Changes in a Multi-Center Clinical Trial. Journal of Dermatology, 1999, 26, 210-215.	1.2	65
1050	Tobacco smoking contributes little to facial wrinkling. Journal of the European Academy of Dermatology and Venereology, 1999, 12, 133-139.	2.4	5
1051	THE EPIDEMIC OF TINEA CAPITIS DISPROPORTIONATELY AFFECTS SCHOOL-AGED AFRICAN AMERICANS. Pediatric Dermatology, 1999, 16, 75-75.	0.9	23
1052	Is prior authorization of topical tretinoin for acne cost effective?. American Journal of Managed Care, 1999, 5, 457-63.	1.1	9
1053	Most topical tretinoin treatment is for acne vulgaris through the age of 44 years: An analysis of the National Ambulatory Medical Care Survey, 1990-1994. Journal of the American Academy of Dermatology, 1998, 38, 221-226.	1.2	30
1054	Psoriasis treatment. Current Problems in Dermatology, 1998, 10, 1-40.	0.0	9
1055	PSORIASIS. Medical Clinics of North America, 1998, 82, 1135-1144.	2.5	5
1056	Most Common Dermatologic Problems Identified by Internists, 1990-1994. Archives of Internal Medicine, 1998, 158, 726.	3.8	73
1057	Interpersonal concerns and psychological difficulties of psoriasis patients: Effects of disease severity and fear of negative evaluation.. Health Psychology, 1998, 17, 530-536.	1.6	89
1058	Interpersonal concerns and psychological difficulties of psoriasis patients: Effects of disease severity and fear of negative evaluation.. Health Psychology, 1998, 17, 530-536.	1.6	37
1059	The Physical, Psychological and Social Impact of Psoriasis. Journal of Health Psychology, 1997, 2, 525-537.	2.3	116
1060	Characterization of β_2 -macroglobulin receptor low density lipoprotein receptor-related protein (β_2 MR/LRP) in White Carneau pigeon peritoneal macrophages: its role in lipoprotein metabolism. Lipids and Lipid Metabolism, 1997, 1344, 171-188.	2.6	6
1061	Procedures for skin diseases performed by physicians in 1993 and 1994: Analysis of data from the National Ambulatory Medical Care Survey. Journal of the American Academy of Dermatology, 1997, 37, 719-724.	1.2	38
1062	The economic impact of psoriasis increases with psoriasis severity. Journal of the American Academy of Dermatology, 1997, 37, 564-569.	1.2	156

#	ARTICLE	IF	CITATIONS
1063	Adult pityriasis rubra pilaris: A 10-year case series. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 959-964.	1.2	87
1064	Commercial Tanning Bed Treatment Is an Effective Psoriasis Treatment: Results from an Uncontrolled Clinical Trial. <i>Journal of Investigative Dermatology</i> , 1997, 109, 170-174.	0.7	46
1065	Cigarette smokers engage in more high risk ultraviolet light behavior and have different ultraviolet light attitudes and beliefs. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1996, 7, 193-195.	2.4	3
1066	Disease Severity Measures in a Population of Psoriasis Patients: The Symptoms of Psoriasis Correlate With Self-Administered Psoriasis Area Severity Index Scores. <i>Journal of Investigative Dermatology</i> , 1996, 107, 26-29.	0.7	88
1067	The Self-Administered Psoriasis Area and Severity Index Is Valid and Reliable. <i>Journal of Investigative Dermatology</i> , 1996, 106, 183-186.	0.7	241
1068	Alternative therapies commonly used within a population of patients with psoriasis. <i>Cutis</i> , 1996, 58, 216-20.	0.3	65
1069	Office-Based Physician Services Provided by Dermatologist in the United States in 1990. <i>Journal of Investigative Dermatology</i> , 1994, 102, 93-97.	0.7	54
1070	Patient Measurement of Psoriasis Disease Severity with a Structured Instrument. <i>Journal of Investigative Dermatology</i> , 1994, 102, 967-969.	0.7	82
1071	Illiteracy and the readability of patient education materials. A look at Health Watch. <i>North Carolina Medical Journal</i> , 1994, 55, 290-2.	0.2	6
1072	Bullous dermatoses associated with systemic disease. <i>Dermatologic Clinics</i> , 1993, 11, 597-609.	1.7	2
1073	The biology and clinical application of systemic glucocorticoids. <i>Current Problems in Dermatology</i> , 1992, 4, 211-235.	0.0	4
1074	Fluconazole treatment of cutaneous cryptococcosis. <i>Archives of Dermatology</i> , 1992, 128, 1045-6.	1.4	2
1075	Immunohistochemical localization of alpha 2-macroglobulin receptors in human skin. <i>Acta Dermato-Venereologica</i> , 1992, 72, 331-3.	1.3	3
1076	In vivo catabolism of α_1 -antichymotrypsin is mediated by the Serpin receptor which binds α_1 -proteinase inhibitor, antithrombin III and heparin cofactor II. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1988, 967, 158-162.	2.4	52
1077	Organic affective disorder in a patient with congenital adrenal hyperplasia. <i>Biological Psychiatry</i> , 1987, 22, 767-770.	1.3	5
1078	Binding of α_2 -macroglobulin to hepatocytes: Mechanism of in vivo clearance. <i>Biochemical and Biophysical Research Communications</i> , 1985, 128, 795-802.	2.1	64
1079	Comparison of the binding of chicken α_1 -macroglobulin and ovomacroglobulin to the mammalian α_2 -macroglobulin receptor. <i>Archives of Biochemistry and Biophysics</i> , 1984, 235, 267-275.	3.0	52
1080	Conformation-specific precipitation of human α_2 -macroglobulin by divalent zinc or calf thymus histone H3. <i>Archives of Biochemistry and Biophysics</i> , 1984, 233, 462-468.	3.0	13

#	ARTICLE	IF	CITATIONS
1081	Circular dichroic spectroscopy of non-human $\hat{\pm}$ -macroglobulins. Biochemical and Biophysical Research Communications, 1984, 123, 771-777.	2.1	22
1082	$\hat{\pm}$ 2-macroglobulin $\hat{\sim}$ fast $\hat{\sim}$ ™ forms inhibit superoxide production by activated macrophages. Biochimica Et Biophysica Acta - General Subjects, 1983, 760, 421-423.	2.4	54
1083	In vitro binding and in vivo clearance of human $\hat{\pm}$ 2-macroglobulin after reaction with endoproteases from four different classes. Biochemical and Biophysical Research Communications, 1983, 114, 757-762.	2.1	45
1084	Psoriasis Regimens. , 0, , 507-513.		0
1085	Psoriasis comorbidities and clinical implications when using biologics. Dermatological Reviews, 0, , .	0.5	1
1086	A narrative review of systematic reviews on adherence to psoriasis treatments. Dermatological Reviews, 0, , .	0.5	0
1087	Emerging Treatment Regimens in Psoriasis: Are There Advantages Over Current Biologic Therapies?. EMJ Dermatology, 0, , 106-121.	0.0	1
1088	Hand Dermatitis Secondary to Exposure to Butternut Squash. Case Reports in Dermatology, 0, , 123-126.	0.8	0
1089	Methotrexate for Cutaneous Sarcoidosis: A Dermatology-Based Case Series of 23 Patients. Journal of Cutaneous Medicine and Surgery, 0, , 120347542211013.	1.2	2
1090	Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data. Clinical, Cosmetic and Investigational Dermatology, 0, Volume 15, 1037-1043.	1.8	6
1091	Fear of Negative Evaluation in Hidradenitis Suppurativa Patients is Correlated with Worse Quality of Life: An Observational Study. British Journal of Dermatology, 0, , .	1.5	0
1092	Review of Calcipotriene and Betamethasone Dipropionate Cream in the Treatment of Psoriasis. Annals of Pharmacotherapy, 0, , 106002802211055.	1.9	0